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1. ZUSAMMENFASSUNG 
Das sogenannte Krankheitsgefühl Syndrom (engl. sickness behavior syndrome, SBS) 
beschreibt die Gesamtheit der Adaptierung des Verhaltens und der Physiologie von viralen 
oder bakteriellen Infektionen der Betroffenen. Es umfasst uns allen begegnete Symptome, wie 
Fieber, Appetitlosigkeit, Verstimmung, Müdigkeit, Lethargie und verminderte soziale 
Interaktion. Nicht bewiesen aber vermutet wird, dass das SBS eine Strategie erfüllt, um die 
Infektionen besser zu bewältigen und das Ansteckungsrisiko zwischen Individuen zu 
minimieren. Bei chronischen Entzündungskrankheiten und in Autoimmunkrankheiten, wie 
zum Beispiel der Multiplen Sklerose, rheumatoiden Arthritis und dem systemischen Lupus 
erythematodes, ist das SBS eher maladaptiv und beeinträchtigt die Lebensqualität der 
Betroffenen sehr stark. 
Eine Vielzahl von wissenschaftlichen Untersuchungen zeigt, dass das SBS durch Aktivierung 
des Immunsystems von Zytokinen hervorgerufen und aufrechterhalten wird. Am häufigsten 
diskutiert sind dies, der Tumor Nekrose Faktor (TNF), Interleukin-1 (IL-1) und Interleukin-6 
(IL-6), für welche gezeigt ist, dass sie Zentren im Hypothalamus erreichen oder alternativ 
über den Nervus Vagus die Funktion des neuronalen Netzwerkes beeinflussen.  
Die molekularen Mechanismen welche zu den von Zytokinen bewirkten Veränderungen der 
Physologie, des Metabolismus und des Verhaltens führen, sind noch wenig untersucht. 
Die Auswirkungen des zirkadianen Systems auf unsere Gesundheit rücken immer mehr in 
allgemeines Interesse. Es wird vermutet, dass zirkadianische Dysfunktionen zu einem breiten 
Spektrum von Krankheiten beitragen, wie zum Beispiel Insomnie und Depressionen.  
Eine steigende Anzahl von Studien zeigt, dass das Immun- und das zirkadianische System 
sich gegenseitig regulieren könnten. Vor kurzem wurde berichtet, dass das Zytokin TNF in 
der Lage ist die Expression der Clock Gene Period, Rev-Erbα und der Clock-kontrollierten 
Gene zu beeinflussen, was auf ein direktes Zusammenspiel zwischen den Clock Proteinen und 
dem Immunsystem hinweist. 
Hier wird gezeigt, dass die Behandlung mit agonistischen anti-CD40 Antikörpern ein 
geeignetes Model darstellt um SBS, welches mit Autoimmunkrankheiten assoziiert ist, zu 
erforschen. CD40 ist ein vor allem auf Antigen präsentierenden Zellen (Dendritischen Zellen 
und Makrophagen) sowie B-Zellen exprimiert. Es wird durch die von T-lymphozyten 
gebildeten CD40 Liganden aktiviert. Hemmung der CD40 Aktivierung führt zu verminderter 
Ausprägung von Autoimmuerkrankungen in Tiermodellen. Wir fanden, dass in Mäusen die 
Verabreichung von agonistischen anti-CD40 Antikörpern zu einer ausgesprochen Reduktion 
 2
der lokomotorischen Aktivität und zu einer Zunahme der ruhenden Periode in der Nacht führt, 
während die Tiere normalerweise aktiv sind. Dieser Effekt wurde auch in Mäuse welche kein 
IL-6 oder kein IL-1R1 exprimieren beobachtet. Dies ganz im Gegensatz zu Mäusen, welche 
keinen TNFR1 exprimieren. Diese Untersuchungen belegen, dass die TNF-TNF Rezeptor 1 
Interaktion für das Auftreten von SBS nach CD40 Aktivierung unabdingbar ist. Dafür 
sprechen auch Untersuchungen von Mäusen, welche kein MyD88 – ein intrazelluläres 
Adaptorprotein das mit Pathogenen Erkennungsstrukturen und IL-1R1 kommuniziert, 
exprimieren. MyD88-/- Mäuse sind genauso wie TNFR1-/- resistent gegenüber Behandlung mit 
agonistischen anti-CD40 Antikörpern, doch diese Mäuse bilden darauf nur vermindert TNF 
im Serum. Eine Verabreichung von rekombinanten TNF führt in diesen Mäusen ebenfalls zu 
SBS.  
Wie schon nach TNF Behandlung von Mäusen gezeigt, war die Amplitude der Expression 
von E-Box kontrollierten Clock Genen in der Leber von agonistischen anti-CD40 Antikörpern 
behadelten Tieren abgeschwächt. Dieser Effekt auf die Expression der Clock Genen, ist 
ebenso wie die Reduktion der Aktivität der Tiere, von TNFR1 abhängig, nicht aber von IL-6 
oder IL-1R1. Das Ausmass der Aktivitätverminderung korreliert mit der Intensität der 
Repression von Dbp in allen untersuchten Genotypen. 
Obwohl der molekulare Mechanismus der hier geschilderten Ergebnisse noch geklärt werden 
muss, zeigen diese Ergebnisse, dass das Immunsystem über TNFR1 die zirkadiane Uhr 
beeinflusst und dadurch zur Entwicklung des SBS führt. 
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2. SUMMARY 
The sickness behaviour syndrome (SBS) describes the collective behavioural and 
physiological adaptations of the host to viral and bacterial infections. It comprises well-
known symptoms, such as fever, loss of appetite, depressive mood, fatigue, reduced social 
interaction and lethargy. It is considered as a strategy to better cope with infections, to 
facilitate recovery, and to decrease the risk of disease transmission among individuals. The 
behavioural changes observed in sick individuals may be indeed advantageous to the infected 
host, in line with experiments showing that sickness behaviour is a motivational state rather 
than just weakness alone. However, in the course of autoimmune diseases, including multiple 
sclerosis, lupus erythematosus, and rheumatoid arthritis, SBS seems to be rather maladaptive, 
and often represents the most debilitating effect compromising the quality of life of the 
affected individuals. Many lines of evidence indicate that SBS is induced and maintained by 
cytokines released by activated immune cells. Among these, tumour necrosis factor-alpha 
(TNF), interleukin-1β (IL-1), and interleukin-6 (IL-6) are the most potent mediators, 
signalling to the brain via humoral and neural pathways. However, their functional hierarchy 
and the molecular mechanisms underlying the physiological, metabolic, and behavioural 
action of these cytokines have not been investigated yet. 
The impact of circadian timing on our health is gaining increasing attention, and circadian 
dysfunction is thought to contribute to the incidence of a wide range of diseases, including 
sleep disorders and depression. An increasing number of studies indicate that the immune 
system and the circadian timekeeping system may mutually regulate each other. Previous 
evidence suggests that the cytokine TNF can modulate the expression of clock genes Bmal1, 
Period, Rev-Erbα and of the clock-controlled genes, suggesting a directly link between core 
clock proteins and inflammatory pathways. 
Here, we report that treatment with CD40 agonists represents a suitable model for studying 
sickness behaviour syndrome associated with autoimmune diseases. The CD40-receptor is 
expressed on the cell surface of B-lymphocytes and of antigen presenting cells, including 
macrophages and dendritic cells. These cells become activated by T-cells, which express 
CD40 ligand (CD40L). Blocking of CD40 activation leads to reduced severity of autoimmune 
diseases in animal models. In this model, TNF is likely the main mediator of the behavioural 
changes observed. We found that injection of CD40 agonists leads to a pronounced 
impairment of locomotor activity and increased rest periods in mice at night, the time period 
when the animals are usually active. This effect was still observed in IL-6 and IL-1R deficient 
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mice, but was not seen in mice lacking TNFR1. Moreover, TNF injections were sufficient to 
induce SBS in MyD88-/- mice, although these animals were resistant to SBS mediated by 
CD40 agonists. MyD88 is an intracellular adaptor protein used by all Toll-like receptors 
(except TLR3) and IL1R1. 
As reported for TNF, the amplitude of the expression of E-box bearing clock genes was 
reduced in the liver of CD40 treated animals. The impairment of locomotor activity as well as 
the dysegulation of clock gene expression depends on TNFR1, but not on IL-6 or IL-1R1 
signalling. The degree of locomotor activity impairment correlates with the intensity of Dbp 
repression and Bmal1 induction in all genotypes analyzed.  
Although a molecular mechanism still needs to be clarified, these results indicate that the 
immune system is indeed able to influence the circadian clock. Interference of the immune 
system with the circadian clock may represent a possible mechanism underlying the 
development of sickness behaviour syndrome. 
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3. INTRODUCTION 
 
3.1 Cytokine-induced sickness behaviour 
3.1.1 The sickness behaviour syndrome 
Everybody has experienced the feeling of being sick after a bacterial or viral infection. 
Typical symptoms of sickness include fever, loss of appetite, weight loss, sleepiness, 
listlessness and fatigue. They are collectively referred to as sickness behaviour syndrome 
(SBS). Initially, it was thought that the behaviour of a sick subject was due to physical 
weakness that resulted from diverting energy to the body processes needed to fight infection. 
Now, however, it is known that sickness represents a complex adaptive response to infection 
or injury required to improve chances of survival and decrease the risk of disease transmission 
among individuals [1].  
The first evidence for the benefits of fever in fighting disease came from experiments by 
Kluger and colleagues. They showed that survival of lizards infected with a pathogen was 
enhanced if the animals were allowed to develop fever [2]. Few years later, in a similar 
experiment performed in rabbits, treatment with an antipyretic agent increased mortality in P. 
multocida infected animals [3]. In 1979, Murray et al. showed that overriding the anorexia of 
mice infected with Listeria monocytogenes by force-feeding, both accelerated the course of 
infection and increased the probability of death [4]. Thus, the development of SBS seems to 
offer survival and healing advantages to many animal species. SBS, however, also represent 
the most disabling consequences for patients with autoimmune diseases [5-8], and have 
stronger debilitating effects on the quality of life of the affected subject than the pain or 
disease associated symptoms themselves. Moreover, increasing evidence suggest that 
inflammation increases the risk of occurrence of major depressive disorders, and pro-
inflammatory cytokines have been implicated as contributing factors [9]. Common to all 
patients suffering from conditions associated with fatigue, due to both infectious and 
autoimmune diseases, are altered levels of cytokines in the blood. 
Already in 1960 it was known that symptoms of sickness were due to blood-derived factors 
acting on the brain [10]. In the 1980s, when IL-1 was first isolated and later on with the 
discovery that TNF induces endotoxic shock, it became clear that these factors were 
cytokines, produced by immune cells in response to endotoxin.  
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Besides being the major signalling molecules of the immune system, cytokines can also act as 
potent neuromodulators. This may help to explain the cytokine-induced CNS derived 
behavioural effects of SBS. The immune system has long been regarded as an immune 
privileged site. However, the last decades provided strong evidence that the central nervous 
system and the immune system are able to communicate with each other, the one system 
being modulated by the other resulting in bidirectional neuroimmune interactions [11]. There 
are many cytokines that can affect brain function and therefore behaviour, but TNF, IL-1, IL-
6 are the cytokines which have been consistently associated with SBS [12]. It is interesting to 
note that systemic or central administration of IL-1, TNF or IL-6 into mice induces the full 
spectrum of behavioural signs of sickness, suggesting that these cytokines are involved in the 
CNS response [9]. Cytokines never act alone, but rather in a complex network in which they 
can induce expression of each other and regulate the expression of their own receptors [12]. 
Although the importance of these cytokines in mediating sickness behaviour has been 
appreciated, there is still limited knowledge about the hierarchy of the involved cytokines, 
their site of action and the interplay between the different modulators involved in a complex 
immune response regulating sickness behaviour.  
 
3.1.2 The immune system regulates the production of cytokines  
Dendritic cells and macrophages, representing the innate immune system, mediate the first 
step of the defence against harmful pathogens. These cells recognize pathogens or 
endogenous danger signals, released upon cellular damage or stress, via pattern-recognition 
receptors (PRRs). The best known of these are Toll-like receptors (TLR), but many other 
receptors are also involved. PRRs bind to conserved microbial components, known as 
pathogen-associated molecular patterns (PAMPs), or endogenous alarmins. Ligand-bound 
PRRs alert the host of danger by activating the immune system, leading to the production of 
pro-inflammatory cytokines by immune cells [13].  
Cytokines have a crucial function in the development, differentiation and regulation of 
immune cells. Therefore, dysregulation of cytokine production or action has a central role in 
the development of autoimmune diseases. Some cytokines, such as TNF and interferon-
gamma are potent promoters of immune and inflammatory responses. However, some 
cytokines have also immunosuppressive functions. The balance between these opposing 
functions of cytokines has to be tightly regulated by the immune system because excessive 
production or inadequate inhibition can be life threatening [14].  
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3.1.3 How the immune system communicates with the CNS 
Cytokines released in the course of an immune response have to reach the CNS in order to 
exert their effect on behaviour. Cytokines are water-soluble molecules of relative large 
molecular weight, and therefore they are not expected to cross the blood brain barrier directly. 
Different mechanism exist by which peripheral cytokines may gain access to the brain: a) they 
may enter directly into the brain crossing the specialized endothelial cells composing the 
blood brain barrier (BBB) by receptor-mediated transport; b) they may reach the brain 
through areas devoid of a BBB, as in the choroid plexus and the circumventricular organs, 
comprising the organum vasculosum of the lamina terminalis and the area postrema; c) or 
they can directly stimulate nerve afferent in the periphery, such as the vagus nerve [12, 15]. 
Peripheral cytokines can also induce production of brain cytokine synthesis at the endothelial 
cells, which express receptors for cytokines. Cytokines expressed by these cells may serve as 
a signal for neurons, astrocytes and microglia cells, which express the cytokine receptors and 
can selves produce cytokine [16-18].  
 
3.1.3 Models of sickness behaviour syndrome 
SBS can be induced by several activators of the immune system.  
So far, administration of lipopolysaccharide (LPS), mimicking bacterial infection, is the most 
commonly used model for sickness behaviour. LPS is a component of the cell wall of Gram-
negative bacteria which is recognized by TLR4, mainly expressed on monocytes and 
macrophages. Activation of TLR4 by LPS results in release of the cytokines IL-1, TNF and 
IL-6 in the periphery as well as in the brain [19-20]. Symptoms of sickness behaviour, such as 
fever, reduced locomotor activity and weight loss are detected as early as two hours after LPS 
injection [21]. This effect is clearly dependent on the dose of LPS. 
Polyinosinic:polycytidylic acid (Poly I:C) is a synthetic double-stranded RNA and is a ligand 
for TLR3. Treatment of mice with this compound mimics the acute phase of viral infection, 
leading to a rapid decrease in open field and burrowing activity, as well as reduction in body 
weight and core body temperature. These effects are accompanied by increased levels of 
cytokine expression in the CNS [22]. 
In the present study we established a new model to study SBS using monoclonal anti-CD40 
antibodies. CD40 is a glycoprotein expressed on the surface of B cells, monocytes, 
macrophages, dendritic cells and microglia, as well as on non-hematopoietic cells such as 
endothelial cells, fibroblasts, and epithelial cells [23]. CD40 is a member of the tumour 
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necrosis factor receptor (TNFR) superfamily that also includes TNFR1, TNFR2 and FAS 
(CD95). Its ligand CD40L (CD154) is a type II transmembrane protein of the TNF gene 
superfamily (which includes TNF, lymphotoxin- and lymphotoxin-, FasL) mainly 
produced by activated CD4+ T-cells. Binding of CD40L to its receptor CD40 results in 
activation of different signalling pathways including the canonical and non-canonical NF-B-
signalling pathway, the mitogen-activated protein kinases (MAPKs), the phosphoinositide 3-
kinase (PI3K), which ultimately lead to the induction of cytokines, i.e. TNF, IL-1, IL-6 and 
IL-12, and chemokine expression [24].  
The CD40-CD40L interaction on CD4+T-cells is crucial for their priming, expansion and 
maturation as effector cells. Excessive signalling through CD40-CD40L interaction is 
associated with numerous autoimmune diseases, including multiple sclerosis, rheumatoid 
arthritis, and systemic lupus erythematosus [25]. On the other hand, antibodies to CD40 
ligand prevented the development of autoimmune diseases in experimental animal models 
[26]. CD40 mAb antibodies bind to CD40 mimicking the exaggerated CD40 activation 
observed in autoimmune diseases, therefore, representing a suitable model to investigate 
sickness behaviour associated with autoimmunity.  
 
3.1.4 Tumour necrosis factor  
At the end of 19th century William Coley was the first to describe necrosis of tumours 
induced by bacterial toxins, later on named Coley toxins. In 1975, Carswell and colleagues, 
while studying hemorrhagic necrosis of tumours produced by endotoxin, found that the serum 
of bacillus Calmette-Guérin (BCG)-infected mice treated with endotoxin contained a 
substance which mimics the necrotic action of endotoxin itself. They named this molecule, 
released by macrophages in response to endotoxin, tumour necrosis factor, TNF. 
In 1987, TNF was found to be the most relevant cytokine in the development of cachexia, the 
progressive weight loss and depletion of muscle mass associated with chronic and 
inflammatory disorders. In this experiment, mice were injected with tumour cells expressing 
TNF. These mice died quicker and showed dramatic weight loss compared to control mice, 
indicating that TNF is responsible for the induction of cachexia [27]. In the mean while, TNF 
has emerged as an important pleiotropic cytokine being one of the mediators of acute phase 
reactions, endotoxic shock, cachexia in chronic diseases, and cell-mediated host defence 
against bacteria and viruses, parasites and tumour cells [28].   
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TNF belongs to the TNF superfamily of ligands, comprising nearly 20 homologues including 
lymphotoxin-, lymphotoxin-, CD40 ligand, and Fas ligand. TNF is synthesized as a 
monomeric transmembrane protein inserted into the membrane as a homotrimer (mTNF) that 
can be cleaved by TACE to release a soluble TNF form (sTNF). Both transmembrane and 
soluble TNF are biologically active. TNF is mainly produced by activated macrophages, but 
also by lymphocytes, natural killer cells, endothelial cells, microglia, astrocytes and neurons. 
TNF is a homotrimer of 157 amino acid subunits and signals through two receptors, TNFR1 
(p55TNFR) and TNFR2 (p75TNFR), both of which also exist as soluble active forms [29]. 
The two receptors differ in their expression profiles and ligand affinity. Because their 
intracellular sequences are largely unrelated, they activate different downstream signalling 
pathways.  
 
 
       Figure 1. TNFR1 signalling pathway [29]. 
 
TNFR1 is expressed in most cell types and preferentially activated by sTNF, although it binds 
mTNF as well. TNFR1 contains a cytoplasmic death domain (DD) which mediates binding of 
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TNF receptor associated death domain (TRADD). After binding of TRADD the adaptor 
proteins receptor interacting protein (RIP) and TNF receptor associated factor 2 (TRAF2) are 
recruited. This complex leads to activation of the transcription factor NF-B inducing cellular 
proliferation, cytokine production and survival signalling [30], and to recruitment of inhibitor 
of apoptosis protein 1 and 2 (cIAP 1, 2), resulting in activation of ERK, JNK, p38 MAP 
kinase, and ceramide/sphingomyelinase pathways. The outcome of a TNF signal is 
determined by the kinetics of JNK activation. Acute and short TNF-induced JNK activation is 
cytoprotective and is mediated by phosphorylated TAK1, whereas prolonged JNK activation 
leads to caspase-mediated apoptosis, where JNK is phosphorylated by ASK1 [31]. 
Furthermore, the TNFR1/TNF complex can be internalized as TNF receptosome, and the 
death inducing signalling complex (DISC) is formed upon association with FADD and 
Caspase 8, resulting in TNF-induced apoptosis [32]. 
Expression of TNFR2 is highly regulated and restricted to cells of the immune system, 
endothelial cells and some neuronal populations. TNFR2 can be fully activated only by 
mTNF. Upon TNF binding the adaptor proteins TRAF1 and TRAF2 are recruited to the 
receptor, leading to activation of cIAPs and NF-B pathways, promoting survival and 
inflammation. 
TNF is involved in a number of biological activities, ranging from cell growth and death, 
development and oncogenesis, to immune, inflammatory and stress responses. Implication of 
TNF in the pathogenesis of a variety of human diseases has been reported, including sepsis, 
rheumatoid, multiple sclerosis, and inflammatory bowel diseases [29].  
Numerous diseases accompanied by severe fatigue, such as plaque psoriasis and rheumatoid 
arthritis, are associated with elevated levels of TNF in the blood. Etanercept, a soluble TNF 
receptor that competitively inhibits the interaction of TNF with its receptors, has been 
successfully applied in the clinic alleviating symptoms of fatigue in patient affected by these 
diseases [33-34]. So far, only few studies addressing the role of TNF in mediating fatigue 
have been performed in vivo. In an LPS-induced SBS model, blocking of TNF action in the 
brain by intracerebroventricular injection of soluble TNF receptor reduced the depressive 
effect of intraperitoneal peripheral injection of LPS. Though, this effect was only seen in IL-
1R1 knockout animals and not in wild type, suggesting that TNF might take over the function 
of IL-1, when this is deficient [35]. Another experiment performed in rat has shown that, 
plasma collected from animals injected with IL-1β into the hypothalamus is able to decrease 
locomotor activity when injected into naïve rats. However, the spontaneous motor activity 
following IL-1β challenge into brain was restored by treatment with Etanercept. This suggests 
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that behavioural changes induced by IL-1 mediated effects in the CNS may result from 
peripheral TNF expression [36].  
 
3.1.4 Interleukin-1 
The IL-1 superfamily is a group of cytokines encompassing IL-1α, IL-1β, IL-1 receptor 
antagonist (IL-1Ra), IL-18, and IL-33. The primary source of IL-1α and IL-1β are blood 
monocytes, macrophages and dendritic cells, whereas fibroblasts and endothelial cells 
normally do not produce these cytokines. They are synthesized as immature proteins which 
are subsequently cleaved and converted into the mature form. Pro-IL-1α is biologically active 
and may be cleaved by calpain to be released as mature IL-1α.  
 
 
 
 
 
 
 
 
Figure 2. IL-1 signaling pathway [37]. 
 
The majority of IL-1α remains intracellular. Pro-IL-1β is biologically inactive and is 
converted into the mature and active form by Caspase-1, which activity is controlled by a 
multiprotein complex known as the 'inflammasome'. IL-1β binds to two different receptors, 
IL-1R1 and IL-1RII. IL-1RII is a negative regulator of the IL-1 system and functions as a 
decoy receptor, which binds IL-1 with high affinity without transducing any signal. After IL-
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1binds to IL-1RI the IL-1 receptor accessory protein (IL-1R-AcP) is recruited to form a 
complex with IL-1/ IL-1RI, and the cytoplasmic domain of both receptors leads to cell 
activation. This activated complex recruits different intracellular adapter proteins, including 
MyD88, IRAK, and TRAF6, activating multiple signalling pathways, including NF-B, JNK 
and p38 MAPK [38-39].  
The IL-1Ra is structurally similar to IL-1. It binds tightly to the IL-1R1 thereby blocking 
access of IL-1 to the receptor [38]. Excessive production of IL-1, causing an imbalance 
between IL-1 and IL1-Ra, is implicated in many autoinflammatory diseases. This pathological 
increase of IL-1 secretion is usually, but not always, due to dysfunctional activation of 
caspase-1 by the inflammasome. Anakinra, a recombinant human IL-1Ra, has been approved 
for the treatment of many IL-1 associated diseases, including rheumatoid arthritis, Still's 
syndrome and type 2 diabetes [40]. IL-1 is a potent activator of host defence in responses to 
infection, injury and inflammation mediating fever, slow-wave sleep, sickness behaviour [37], 
and modulating the neuroendocrine system, especially the hypothalamic pituitary-adrenal axis 
[41]. 
Mice deficient in IL-1R1 are fully responsive to sickness-inducing effects of LPS treatment, 
manifesting increased immobility, and decreased body weight and food intake. 
Administration of soluble TNF receptor ameliorates these symptoms, though only in IL-1R1 
deficient animals and not in wild type controls. Injection of TNF in IL-1R1 knockout animals 
still induced sickness symptoms. This study by Bluthé et al [35] indicates that both IL-1 and 
TNF can actually mediate LPS-induced sickness symptoms. It has been shown that IL-1 and 
TNF share numerous biological activities, indeed. For instance, both have proinflammatory 
activities, can induce shock-like symptoms, activate the hypothalamic-pituitary adrenal axis, 
induce fever and hypersomnia and suppress food intake. Moreover, IL-1 and TNF often have 
additive or synergistic effects [42], they can induce expression of each other and also regulate 
expression of their own receptors [12]. 
 
3.1.5 Interleukin-6  
Interleukin-6 (IL-6) is produced by various cell types, such as monocytes, B and T cells, 
fibroblasts, endothelial cells and astrocytes. IL-6 binds to IL-6 receptor (IL-6R) to form the 
IL-6/IL-6R complex that binds the membrane bound signal transducing protein gp130. The 
IL-6R also exists in a soluble form which binds IL-6 and forms a complex with gp130 [43]. 
Engagement of gp130 leads to activation of the receptor-associated kinases JAK1, JAK2, and 
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Tyk2, and phosphorylation of tyrosine residues in the cytoplasmic tail of gp130, that control 
the activity of the transcription factors STAT1/STAT3 and the phosphatase SHP2 cascade.  
IL-6 is a pleiotropic cytokine that regulates antigen-specific immune responses and 
inflammatory reactions. It plays a key role in inflammation, being the major inducer of C-
reactive protein, fibrinogen and serum amyloid A protein. A variety of studies have 
demonstrated that overproduction of IL-6 contributes to the pathogenesis of various 
autoimmune and inflammatory diseases, such as inflammatory bowel diseases, rheumatoid 
arthritis, osteoporosis and psoriasis [44].  
 
 
 
Figure 3. IL-6 signalling pathway [45]. 
 
The function of IL-6 in mediating sickness behaviour has been investigated in mice lacking 
the cytokine. In this study, IL-6 deficient mice were found to be less affected by systemic and 
central injection of LPS compared to control animals, suggesting a role for IL-6 in the 
behavioural response to LPS [21]. 
 
 
3.2 Circadian rhythms 
3.2.1 History and meaning of the circadian clock 
Until mid of the 19th century it was believed that daily rhythms in behaviour, such as sleep 
and wakefulness, merely reflects responses to the alteration of light and darkness in the 
environment. This interpretation was first questioned in 1729 by the French geophysicist Jean 
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Jacques Ortous de Mairan. Intrigued by the daily opening and closing of the leaves of a 
Mimosa plant, he tested if this biological "behaviour" was simply a response to the sun. To do 
so, he confined a plant to the dark. The daily rhythmic motions of the leaves persisted even in 
constant darkness [46]. The existence of an endogenous clock became widely accepted only 
in the 1950’s when Curties Richter observed that the periodicity in the activity of mice was 
conserved in constant darkness [47]. By now, it is known that daily rhythms in many 
physiological functions are present in a variety of organisms, from cyanobacteria to 
Neurospora and plants, from Drosophila to birds and mammals. The circadian system permits 
the organism to anticipate periodic events in the environment and to initiate slow processes 
before they are required. Nearly all aspects of mammalian physiology follow a 24-h cycle. 
The most striking result of such an organization is the alternation of sleep and wakefulness, 
but many other functions such as core body temperature, hormone secretion, blood pressure 
and immune responses, lipid and carbohydrate metabolism, and even cell-cycle progression 
are organized in such a temporal way [48]. These self-sustained oscillations with periods 
close to 24 hours are called circadian rhythms. 
 
3.2.2 Anatomical basis of circadian rhythms in mammals 
Circadian rhythms are generated by autonomously active cellular clocks residing in most 
tissues of the body, which, in mammals, are coordinated by a master pacemaker located in the 
suprachiasmatic nuclei (SCN) of the anterior hypothalamus. The SCN is composed of two 
paired nuclei of approximately ten thousand neurons each, containing autonomous cellular 
oscillators [49]. In the absence of external time cues, these oscillators generate cycle slightly 
shorter than 24 hours in mice and slightly longer in humans, and therefore its phase must be 
daily readjusted. This task is accomplished by the retinal ganglion cells that collect light 
information via melanopsin photoreceptors and project to the core region of the SCN via the 
retinohypothalamic tract [50]. The major neurotransmitters involved in resetting the SCN 
from the retinohypothalamic tract are glutamate and PACAP [51]. Neurons of the SCN 
include two subpopulations, the one characterized by the expression of the neurotransmitter 
vasoactive intestinal polypeptide (VIP), the other by the expression of the neurotransmitter 
arginine vasopressin (AVP) [52]. 
The key experiment proofing that the SCN is the central pacemaker was performed by 
Michael Menaker and colleagues [53-54]. They discovered different groups of golden 
hamsters with different periods in their locomotor activity. Lesion of their SCN caused 
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arrhythmic behaviour. However, once transplanted with an SCN derived from a hamster with 
a different endogenous period, the rhythm of the recipient animal was restored. Strikingly, the 
period was the one of the donor, meaning that the SCN is indeed the organ that imposes the 
rhythm. Furthermore, when the donor SCN was transplanted in SCN-lesioned hosts 
encapsulated in a semiporous membrane, preventing in this way the formation of neuronal 
connections, the circadian rhythm of locomotor activity was still restored [55]. This implies a 
diffusible factor that is able to deliver signal s from the SCN to the periphery. Recently, 
different molecules, such as transforming growth factor-alpha (TGF-α) [56], prokineticin-2 
(PK2) [57] and cardiotrophin-like cytokine (CLC) [58], have been found to be secreted in a 
circadian way and are able to inhibit spontaneous locomotor activity. The rhythms of 
melatonin and corticosteroid secretion have been shown to need synaptic connections [59-60]. 
Projections from the SCN to nearby hypothalamic structures and brainstem then coordinate 
behaviour and physiology. Neurons within the dorsal subparaventricular zone (SPZ) of the 
hypothalamus are necessary for organizing circadian rhythms of body temperature, whereas 
neurons in the ventral SPZ are needed for rhythms of sleep and waking. The ventral SPZ in 
turn relays to the dorsomedial nucleus, which generates circadian rhythms of sleep and 
waking, locomotor activity, feeding and corticosteroid production [61]. 
Feeding time is the major Zeitgeber that entrains the phase of peripheral oscillators. Feeding 
mice exclusively during the day gradually inverses the phase of circadian gene expression in 
peripheral organs such as liver, pancreas, skeletal muscle and kidney, while the phase of the 
SCN remained unaffected [62]. However, as soon as food is available ad libitium, the 
peripheral clocks are quickly resynchronized with the SCN. Because this resetting is much 
faster than desynchronization when shifting feeding from night to day time, it is thought that 
the SCN might also use direct cues to synchronize peripheral clocks. Glucocorticoid 
signalling has been proposed as messenger molecule in this process [63].  
 
3.2.2 The molecular organization of the mammalian clock 
At the molecular level, the mammalian clock consists of interacting positive and negative 
transcriptional feedback loops that drive rhythmic transcription and translation of key clock 
components (reviewed in [64]). In this model, heterodimers of CLOCK and BMAL1 proteins 
bind to E-box regulatory DNA sequences to activate the expression of Per (Period 1, 2) and 
Cry (Cryptochrome 1, 2) genes at the beginning of the circadian day. Approximately 12 h 
later, when PER and CRY levels have reached their highest concentration in the cytoplasm, 
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they form heterodimers that enter the nucleus and bind to the CLOCK:BMAL1 complex, 
suppressing E-box driven gene transcription. When the levels of Per and Cry transcripts 
decrease, the inhibition of the CLOCK:BMAL1 complex is released and another cycle can 
begin. Clock mRNA and protein are constitutively expressed, whereas Bmal1 mRNA 
expression cycles in antiphase to that of Per and Cry. This delayed expression of Bmal1 
depends on an accessory loop involving the nuclear orphan receptors, REV-ERBα and RORα. 
Because Rev-Erbα and RORα bear E-box sequences in their promoters, their expression is 
also driven by CLOCK and BMAL1 heterodimers and therefore rhythmically in phase with 
Per and Cry. REV-ERBα and RORα bind to the ROR element of the Bmal1 promoter through 
RORE sequences, respectively inhibiting and activating Bmal1 transcription [65] (Fig 4).  
CLOCK:BMAL1-mediated transactivation is associated with rhythmic changes in histone 
acetylation, suggesting that chromatin remodelling is an important regulatory mechanism in 
the circadian clock machinery. The CLOCK protein itself possesses an intrinsic 
acetyltransferase activity specific for histone and BMAL1. The acetyltransferase activity of 
CLOCK is counterbalanced by sirtuin 1 (SIRT1), which deacetylases PER2 and BMAL1 [66]. 
Besides direct transcriptional control, clock proteins are regulated at the posttranslational 
level through various modificatons, such as phosphorylation [67], sumoylation [68], histone 
acetylation [69] and methylation [70], which regulate the localization, degradation and 
activity of the core clock proteins, contributing to the generation of a 24 hours period.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The molecular clock, adapted from [65]. 
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3.2.3 The output of the clock 
The circadian oscillator regulates behavioural, physiological, and metabolic rhythms by 
activating output pathways at the appropriate time of the day. Microarray studies revealed that 
3-10% of all expressed transcripts are under circadian regulation [71]. Rhythmic genes are 
expressed in a tissue-specific manner, with only a minor overlap between tissues, reflecting 
the tissue specificity of different rhythmic outputs [72]. These transcripts include key and rate 
limiting enzymes involved in various aspects of physiology and metabolism, such as protein 
synthesis and turnover, energy production and nutrient metabolism. In the liver, for example, 
rate-limiting steps of glycolysis, fatty-acid metabolism, cholesterol biosynthesis, and 
xenobiotics metabolism are under tight circadian control. 
These rhythmically expressed downstream genes are called clock-controlled genes (CCGs) 
and their expression may be directly or indirectly depend on core clock components. Directly 
controlled genes harbor E-boxes or ROR elements in their promoter, and therefore depend on 
CLOCK:BMAL1 complexes and REV-ERBα respectively for activation. Among the CCGs 
directly controlled by CLOCK are the members of the PAR-bZip (proline and acidic amino 
acid-rich basic leucine zipper) transcription factor family: Dbp (D-site albumin promoter 
binding protein), Tef (Thyrotroph embryonic factor) and Hlf (Hepatic leukemia factor). These 
proteins activate transcription of downstream genes bearing the consensus sequence 
RTTAYGTAAY [73]. All three PAR bZIP genes are cyclically expressed in the SCN [74]. 
DBP and TEF accumulate in most cell types, whereas expression of HLF is restricted to liver, 
kidney and brain. When all three genes are inactivated, most of the mice die because of 
spontaneous epileptic seizures shortly after birth. This might be explained by reduction of 
Pyridoxal Kinase (Pdxk) expression observed in these mice. PDXK converts vitamin B6 
derivatives into pyridoxal phosphate (PLP), an essential co-enzyme involved in the 
metabolism of different neurotransmitters, like serotonin and dopamine. These mice have 
indeed lower amounts of these neurotransmitters, which may be the cause for the lethal 
epileptic seizures. Furthermore, triple knockout mice for DBP, HLF and TEF, also show signs 
of early aging, and less than 20% of the animals survive longer than one year. DBP, HLF and 
TEF have been found to control transcription of enzymes regulating defence against 
xenobiotics and oxidative stress, explaining the strong phenotype observed in triple knockout 
animals. 
Of the three PAR transcription factors, DBP is the one with the highest abundance and the 
largest circadian oscillation. Studies in Dbp knockout mice evidenced a role for DBP in 
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controlling circadian behaviour, although its precise role in the central pacemaker is still 
unknown. Mutant mice still exhibit a circadian behaviour, but have a 30 minutes shorter 
period and are 64% less active than wild type animals [74]. 
Furthermore, the DBP deficiency affects the distribution of sleep episodes during the day with 
more episodes during the active period. These mice also had lower level of slow wave sleep 
delta power, which reflect a homeostatic process underlying the regulation of SWS propensity 
[75]. 
 
3.2.4 The clock and its impact on physiology 
As mentioned above, circadian rhythms affect a variety of physiological processes and 
disruption of normal circadian biology has been associated with a series of pathologies, 
including cancer, sleep and metabolic diseases. 
Since the cycle of cell division is under circadian control [76], it is not surprising that cancer 
has been suggested to be a circadian-related disorder. Mutations in some clock genes are 
associated with increased cancer risk. A polymorphism in Per3 has been linked to early onset 
of breast cancer in women, and abnormalities in Per1, Per2 and Per3 expression are observed 
in tumours [77]. Furthermore, tumours grow faster in mice that have their SCN ablated [78], 
or mice that are exposed to irregular night-dark cycles [79], and shift work or jetlag may 
contribute to a higher risk of cancer and increased mortality in humans [80].  
Some of the circadian master genes have been shown to influence sleeping behaviour. A point 
mutation in human Per2 has been found in subjects affected by advanced sleep phase 
syndrome (FASP), a disorder characterized by very early sleep onset and offset [81-83]. 
Circadian rhythm abnormalities have also been described in unipolar depressive and bipolar 
disorders [84]. Animals with mutations in clock genes have been found to have metabolic 
disorders. For instance, homozygous Clock mutant mice have altered feeding rhythms and 
develop metabolic syndrome with obesity, hyperlipidemia, hyperglycemia, and 
hyperinsulinemia and diabetes [85]. In addition to disruption of circadian function, Bmal1 
deficiency results in reduced body weight, early aging accompanied by sarcopenia, 
osteoporosis, reduced lifespan and peripheral blood composition [86]. Moreover, conditional 
ablation of pancreatic clock in pancreas-specific Bmal1 mutant mice leads to increased 
glucose tolerance and increased insulin resistance, resulting in hyperglycaemia [87]. The 
importance of the circadian system in regulating multiple physiological and metabolic 
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processes is evidenced by the phenotype observed in mutant mice. These are summarized in 
table 1. 
 
Table 1, adapted from [88]. 
 
Gene Circadian phenotype Associated physiological abnormality 
Bmal1/Mop3 
null mutant 
Loss of circadian activity 
rhythm in DD 
Infertility, decreased adult body weight, increased tendon 
calcification, abnormal gluconeogenesis and lipogenesis, 
premature aging syndrome, increased sleep fragmentation 
Clock ∆19 
4 h longer period followed 
by loss of circadian activity 
in DD 
Hyperphagic and obese, abnormal gluconeogenesis, mania 
phenotype, decreased duration of sleep time 
Clock null 
mutant 0.5 h shorter period N.D. 
Per1 null 
mutant 0-0.5 h shorter period Lack of sensitization to cocaine 
Per2, 
Per2tm1Brd 
1.5 h shorter period and 
tendency for loss of circadian 
rhythm 
Increased tumour development following genotoxic stress, 
improper alcohol intake, early onset of sleep 
Per1 and 
Per2 double 
null mutant 
Complete loss of circadian 
activity rhythm in DD N.D. 
Per3 null 
mutant 0-0.5 h shorter period N.D. 
Cry1 null 
mutant 1 h shorter period N.D. 
Cry2 null 
mutant 1h shorter period N.D. 
Cry1 and 
Cry2 double 
mutant 
Complete loss of circadian 
activity rhythm in DD 
Delayed hepatocyte regeneration, increased resistant to 
chemotherapeutic agent's toxicity, increased NREM sleep 
drive 
Rev-Erbα 
null mutant 
0.5 h shorter period, altered 
photic entrainment N.D. 
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3.2.5 The circadian clock and the immune system 
A number of lines of evidence suggest that cytokines and other immune mediators can 
influence circadian timekeeping processes, and likewise that the immune system may be 
under the circadian control. 
The circadian clock has been characterized in peritoneal macrophages, and the expression of 
several clock genes such as Bmal1, Rev-Erbα, Per1, Per2 and Dbp exhibited diurnal 
variation. Furthermore, the expression of the inflammatory factor MCP-1 (monocyte 
chemoattractant protein-1) as well as the phagocytic activity of isolated macropahges showed 
a robust circadian pattern [89]. Fully competent circadian clocks also exist in splenocytes and 
lymph nodes. Secretion of TNF and IL-6 by spleen macrophages challenged with LPS also 
displayed a significant circadian oscillation. In addition, as revealed by microarray analysis, 
approximately 8% of the genes expressed in macrophages are under circadian regulation. 
Among these were canonical clock genes like Bmal1, Per1, Per2, Per3, Rev-Erbα, Cry1, 
Cry2 as well as Dbp [90]. Different functions of natural killer (NK) cells, such as expression 
of the cytolytic factors Granzyme B and Perforin, as well as the cytokines TNF and IFNγ 
have been reported to follow a circadian pattern [91]. 
Recently, Cavadini et al [92] have shown that TNF directly regulates the expression of E-box 
driven clock genes, such as Per1, 2, 3 as well as Dbp, Hlf and Tef in cultured fibroblasts. This 
effect on clock gene expression was also found in liver of TNF treated mice and was 
accompanied by an increase in rest episodes.  
The effect of intravenous injection of LPS on clock genes has been investigated in rats. This 
study showed that LPS suppresses the expression of Per and Dbp in the SCN, and 
downregulates the expression of Per1, Per2, Dbp and PPARα in the liver of treated animals 
[93]. Taken together, these findings lead to the question whether and to what extent the 
behavioural effects of centrally acting cytokines and other immune mediators are mediated 
via the circadian clock.  
 
 
 
 
 
 
 
 21
3.3 Aim of the project 
The role of the immune system in clearance of pathogens and tissue destruction in infectious 
and autoimmune diseases has been mostly clarified. Though, the molecular mechanisms 
underlying the physiological, metabolic, and behavioural changes evoked by the activated 
immune system have been poorly investigated so far.  
Here, we aimed at establishing a mouse model for studying SBS associated with chronic T-
cell dependent inflammation. Agonistic anti-CD40 antibodies were used to mimicking the 
action of T-cell derived CD40 ligand. These antibodies are known to induce the full spectrum 
of sickness behaviour symptoms and to activate the peripheral immune system inducing the 
synthesis TNF, IL-1, and IL-6. We especially focus on locomotor activity behaviour and 
weight loss as read out for SBS. 
To address the role of TNF, IL-1, and IL-6 in the induction of SBS anti-CD40 antibodies were 
applied to mice deficient for either the cytokine or the cytokine receptor. Moreover, the 
impact of CD40-mediated immune activation on the molecular clock was assessed.  
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SUMMARY 
Infectious and autoimmune diseases are associated with fever, fatigue, reduced appetite,and 
depression. These symptoms are collectively referred to as sickness behaviour syndrome 
(SBS). SBS is particularly debilitating in many autoimmune diseases including, multiple 
sclerosis and rheumatoid arthritis. It is a common belief that these symptoms are mainly 
caused by the action of cytokines TNF-, IL-1 and IL-6. However, it is still unclear which 
cytokine is essential for the development of SBS. Moreover, the mechanisms leading to the 
SBS have been poorly investigated so far. 
Here we present a model for investigating SBS associated with autoimmune diseases using 
anti-CD40 antibodies. In this model SBS evoked by CD40 activation is mediated by 
TNF:TNFR1 interaction and does not depend on IL-1R1 or IL-6. The intensity of the CD40 
evoked SBS correlates with suppression of E-box controlled clock genes including Dbp, 
Bmal1 and Rev-Erbα. Thus, our results suggest that SBS development in autoimmune 
diseases is dependent on CD40-mediated TNF expression and indicate a role for 
dysregulation of the circadian clock. 
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INTRODUCTION 
Infectious and autoimmune diseases are associated with fever, fatigue, reduced appetite and 
depression. These symptoms are referred to as sickness behaviour syndrome (SBS). SBS is 
considered an adaptive strategy to better cope with infections, to facilitate recovery, and to 
decrease the risk of disease transmission among individuals. In the course of autoimmune 
diseases, including multiple sclerosis, lupus erythematosus (SLE), and rheumatoid arthritis 
(RA), SBS is rather maladaptive, and often represents the most debilitating effect 
compromising the quality of life of affected individuals. For instance, incidence of fatigue has 
been reported in 91% of SLE patients [94], and severe fatigue, perceived as frustrating or 
exhausting, is experienced in 42% of RA patients [7]. Many lines of evidence indicate that 
SBS is induced and maintained by cytokines such as tumor necrosis factor alpha (TNF), 
interleukin (IL-) 1 and -6, which are produced in the course of an immune response [12]. 
Clinical observations suggest a causal link between TNF and fatigue in autoimmune diseases. 
Treatment with the soluble TNF receptor p75 improved fatigue in patients with RA [33, 95]. 
Moreover, in multiple sclerosis, fatigue correlated with TNF expression in blood leukocytes 
[6]. However, it is presently unclear which cytokine-cytokine receptor system is responsible 
for SBS.  
Since no animal model exists to investigate the pathogenesis of SBS in autoimmune diseases, 
we established a new mouse model using agonistic antibodies to CD40. CD40 receptor is 
expressed on B lymphocytes and antigen presenting cells (APC), namely dendritic cells and 
macrophages. Its binding to CD40 ligand (CD40L, CD154), secreted by activated CD4+ T 
lymphocytes, stimulates APC to produce cytokines such as TNF, IL-1, and IL-6 [23-24, 96]. 
Antibodies against CD40L prevent TH1-mediated autoimmune diseases including SLE and 
RA Durie [26, 97-98]. Antibodies to CD40 or soluble CD40L have therapeutic potential in the 
treatment of lymphoproliferative malignancies and solid tumours. However, their applicability 
is limited due to the occurrence of SBS with fatigue, anorexia and headache [99]. 
The molecular mechanisms leading to the physiological, metabolic, and behavioural changes 
observed in SBS are presently unclear. Circadian dysfunction is thought to contribute to the 
incidence of a wide range of diseases, including sleep disorders and depression. Circadian 
rhythms are maintained by basic helix-loop-helix (bHLH)-PAS transcription factors CLOCK 
and BMAL1, which bind as a dimeric complex selectively to E-boxes (CACGTG/T) in the 
promoters of the Per (Per 1-3) and Cry (Cry 1-2) genes and of clock-controlled genes (CCGs) 
such as the PAR bZIP transcription factors Dbp, Tef and Hlf [64, 100]. PER and CRY 
proteins translocate to the nucleus and repress the activity of CLOCK and BMAL1, thereby 
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inhibiting their own transcription. The transcription of Rev-Erbα is positively regulated by 
CLOCK:BMAL1 and negatively by PER2. REV-ERB binds to the ROR elements (ROREs) 
in the Bmal1 promoter driving the rhythmic transcription of the latter [101].  
Recently, we found that TNF impairs the expression of E-box driven clock genes, including 
the PAR bZip transcription factors Dbp, Tef and Hlf, as well as Per, Cry and Rev-Erb. The 
effect of TNF is seen in murine fibroblasts in-vitro and upon subcutaneous infusion of TNF in 
also in livers of treated mice [92]. Inducers of TNF, namely LPS, have also been shown to 
suppress the expression of clock genes [93]. These data indicate a possible crosstalk between 
the circadian clock and the cytokine network. 
 The aim of our study was to investigate which cytokine is essential for the development of 
SBS and to assess the impact of CD40-mediated immune activation on the expression of 
clock genes.  
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RESULTS 
CD40 ligation induces TNFR1-dependent changes in behaviour 
Wildtype (wt, C57BL/6J) mice were treated with agonistic CD40 monoclonal antibodies 
(CD40 mAb) intraperitoneally and their locomotor activity was monitored using running 
wheels and infrared activity detection devices. Significant reduction in locomotor activity was 
observed in CD40 mAb treated wt mice compared to mice receiving isotype control 
antibodies. Marked reductions were seen one day post injection between ZT17 - 21 (Fig. 1 
and Supplementary Fig. 1). Impaired locomotor activity was evident in the 12-h dark period 
mainly due to an increase in rest episodes - indicators of sleep induction - lasting more than 5 
minutes (Supplementary Fig. 3). During the light period, when mice usually rest, no changes 
in locomotor activity or rest were observed, indicating that the daily distribution of activity 
remained within the normal pattern. To assess the contribution of TNF, IL-1 and IL-6, the 
main actors in the development of SBS, CD40 mAb were injected into mice with a deletion of 
the Tnfr1, the Il1r1, and the Il6 gene. As seen in wt mice, IL-6-/- mice responded with a 
significant impairment of locomotor activity and an increase in rest episodes longer than 5 
min. (Fig. 1, Supplementary Fig. 1, 2 and 3). Likewise, the deletion of IL-1R1 did not protect 
mice from CD40 ligation-induced SBS. However, the effect in IL-1R1-/- was less pronounced 
compared to wt (Fig. 1, Supplementary Fig. 1, 2 and 3). TNFR1 deficient mice treated with 
CD40 mAb showed almost complete protection from loss of locomotor activity as measured 
by running wheel (Fig. 1) and infrared activity (Supplementary Fig. 1). Likewise, rest 
episodes were not increased (Supplementary Fig. 3). Heterozygous TNFR1 mice showed 
intermediate reduction of activity suggesting a gene dosage effect of TNFR1 (Supplementary 
Fig. 4). Taken together, TNFR1 seems to be essential in CD40-mediated fatigue as reflected 
by locomotor activity.  
Taking into account all the reports on SBS mediated by LPS and IL-1, we assessed the effect 
of CD40 mAb in MyD88-/- mice. MyD88 is an intracellular adaptor molecule, mainly used by 
TLRs (except TLR3), IL18R and IL-1R to activate the transcription factor NF-B as well as 
interferon-responsive factors [102]. Surprisingly, MyD88-/- mice were resistant to CD40 
mediated SBS as evidenced by their locomotor activity, and rest episodes (Fig. 2, 
Supplementary Fig. 2 and 3). Heterozygous MyD88+/- mice were fully susceptible to the 
respective effect of CD40 mAb (Supplementary Fig. 4). Resistance of MyD88-/- mice is 
unlikely to depend on IL-1 signalling because, as shown above, IL-1R1-/- mice did develop 
SBS. 
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Figure 1. CD40 ligation does not affect locomotor activity in TNFR1-/- mice.  
A) Running wheel activity for the first day after i.p. injection of 200 µg CD40 mAb (red line) or IgG2a as 
control (blue line). Baselines are the mean of three days preceding injection of CD40 mAb (black line) or IgG2a 
control (gray line). Mean of 1-h values ± s.e.m. Note the reduced activities upon CD40 mAb treatment (red 
lines) in wt, IL-6-/-, and IL-1R1-/- are not present in TNFR1-/- mice. B) Difference in running wheel activity after 
subtracting the baseline. Blue line: IgG2a; Red line: CD40 mAb. The data are shown as means ± s.e.m. Stars 
indicate 1-h interval which differed significantly between treated and baseline groups: *P< 0.05, **P <0.005, 
***P< 0.0005, 2-tailed t-test after significant 2-way ANOVA for ‘interval’ and ‘treatment’. C) 24-h actograms 
of running wheel activity of five representative mice per group. Each line represents one individual mouse, one 
day before (baseline, BL) and one day after injection of IgG2a and CD40 mAb. The light-dark period is 
indicated by the black and white bars at the top of the plot. Data are from wt (IgG2a), n = 10; wt (CD40 mAb),  n 
= 12; IL-6-/- (IgG2a), n = 9; IL6-/- (CD40 mAb), n = 11; TNFRI-/- (IgG2a), n = 10; TNFR1-/- (CD40 mAb), n = 11;  
IL-1R1-/- (IgG2a), n = 11; IL-1R1-/- (CD40 mAb), n = 11; for A and B. 
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We speculated that TNF may be involved in the phenotype observed when using MyD88-/- 
mice because (1) MyD88-/- mice have been shown to be low producers of TNF in response to 
TLR activation and, (2) we find CD40 ligation-induced SBS to depend on TNFR1. Indeed, 
treatment of MyD88-/- mice with CD40 resulted in significantly lower TNF concentration in 
the serum compared to wt mice (Supplementary Fig. 5). To address if low level of TNF 
production is responsible for resistance to SBS induction, we administered TNF to MyD88-/- 
mice using osmotic minipumps placed subcutaneously. As observed in wt mice, TNF was also 
able to restore CD40-mediated SBS in MyD88-/- mice (Fig. 2). Thus, TNF seems to be the 
crucial factor in the induction of SBS in MyD88-/- mice. 
 
 
Figure 2. Sickness behaviour syndrome does not develop in CD40 mAb treated MyD88 -/- mice, but can be 
induced by TNF. A) Running wheel revolutions per hour in CD40 mAb treated MyD88-/- mice (red line) and 
IgG2a control (blue line) and the respective baseline for CD40 mAb (black line) and control IgG2a (gray line). 
No effects in CD40 treated mice. B) Difference in running wheel activity after subtracting the baseline. Blue 
lines: IgG2a; red lines: CD40 mAb. The data are means ± s.e.m. C) 24-h actograms of running wheel activity of 
five representative mice per group. Each line represents one mouse, one day before (baseline, BL) and one day 
after i.p. injection of IgG2a and CD40 mAb. D) Changes in locomotor activity three days after implantation of 
the minipump, which releases TNF (1.5 μg/day) or saline as control, compared with the baseline (mean of three 
days immediately before the implantation). Gray line: wt baseline; Black line: MyD88-/- baseline; Blue line: wt 
TNF infused; Red line: MyD88-/- TNF infused. Stars (wt) and crosses (MyD88-/-) indicate 1-h intervals which 
differed significantly between TNF-infused and saline groups: *,+P < 0.05, 2-tailed t-test after significant 2-way 
ANOVA for ‘interval’ and ‘treatment’. E) 24-h actograms of running wheel activity of five individual mice 
before and after minipump implantation. Each line represents one individual mouse, one day before (baseline, 
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BL) and 3 days after the implantation (OP). The light-dark period is indicated by the black and white bars at the 
top of the plot. The data are from MyD88-/- (IgG2a), n = 8; MyD88-/- (CD40), n = 10; for A and B. Or from 
MyD88-/- (Saline), n = 5; MyD88-/- (TNF), n = 5; for D. 
 
In wt mice the effect on locomotor activity was associated with significant weight loss (-
11.7% ± 3.5) compared to isotype-treated animals (-1.9% ± 1.7, P < 0.001) at day two post 
injection (Fig. 3). Whereas mice deficient for IL-6 showed dramatic weight loss (-9.9% ± 1.9, 
P < 0.001), IL-1R1 deficient mice had much less reduction in body weight (-4.0% ± 2.1, P = 
0.003). In TNFR1 deficient mice weight loss was only minimal, but still significant (-2.1% ± 
2.3, P = 0.01), and TNFR1 heterozygous mice developed intermediate weight loss (-4.4% ± 
2.9, P < 0.005). Interestingly, MyD88-/- mice were completely resistant to CD40- induced 
weight loss (-2.3% ± 2.1, P = 0.3). Thus, it certainly appears that TNFR1 and IL-1R1 are 
critically involved in inflammation-induced weight loss triggered by CD40 ligation, while IL-
6 has no effect in this respect. In contrast to the loss of body weight, which depended on the 
knockout mouse line used, CD40 ligation-induced splenomegaly was seen independent of the 
genotype (Fig 3). 
 
 
 
Figure 3. CD40 induced weight loss, but not the increase of spleen size, differs between genotypes. A) Body 
weight measured two days post injection of CD40 mAb (filled dots) or control IgG2a (open dots), is shown as 
percent of body weight before injection (100%). *P< 0.05, **P< 0.005, ***P< 0.0005, Mann-Whitney test.  B) 
Spleen weight measured two days post injection. White bars: IgG2a; Gray bars: CD40 mAb. The data are means 
+ SD. Data are from wt (IgG2a), n = 10; wt (CD40),  n = 12; IL-6-/- (IgG2a), n = 9; IL6-/-(CD40), n = 11; TNFRI-
/- (IgG2a), n = 10; TNFR1-/- (CD40), n = 11;  IL-1R1-/- (IgG2a), n = 11; IL-1R1-/- (CD40), n = 11; MyD88-/- 
(IgG2a), n = 8; MyD88-/- (CD40), n = 10; for A and B. 
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Impaired clock gene expression in CD40 mAb treated mice  
We next asked whether CD40 ligation, besides inducing SBS in a TNFR1-dependent way, 
might also lead to altered expression of clock genes. We have recently identified TNF to 
decrease the expression of clock genes in mice [92]. CD40 ligation in livers of wt mice was 
followed by an increase of Bmal1 expression with upregulation at ZT5 and ZT9 (Fig. 4). The 
expression of Clock was downregulated at ZT1 and ZT5. Rev-Erb, Per2 and Per3 clearly 
show attenuated expression of their amplitudes. The expression of the clock-output genes 
Dbp, Hlf, Tef was dramatically suppressed at the time points where the expression of the 
respective genes showed a peak (Fig. 4). In the kidney, similar changes, namely upregulation 
of Bmal1, and marked down regulation of Dbp, Hlf, Tef, Rev-Erb, and Per3, were detected 
(Supplementary Fig. 6). Thus, the effect of CD40 ligation on clock gene expression is not 
restricted to the liver.  
 
 
Figure 4. Circadian gene expression of clock and clock-controlled output genes are severely impaired by 
CD40 treatment. Gene expression in mouse liver during a 24 h time period (one day p.i., ZT0 lights on, ZT12 
lights off) quantified by RT-PCR. CD40 mAb induce Bmal1 at ZT5 and ZT9, reduce Clock and reduce 
amplitudes of the E-box dependent clock genes Rev-Erbα, Per2, Per3, and clock-output genes Dbp, Hlf, and Tef. 
Three mice per time point and treatment group were analyzed. Mean ± s.e.m. Student's t-test. * P< 0.05, ** P< 
0.005, *** P< 0.0005.  
 31
In further experiments we assessed the effect of CD40 ligation on Dbp, Rev-Erb and Bmal1 
at ZT9 two days after injection in the same knockout mice which we had used to assess 
locomotor activity. IL-6-/- mice showed similar expression pattern as seen in wt mice (Fig. 5). 
In TNFR1-/- mice downregulation of Dbp and Rev-Erb and upregulation of Bmal1 was less 
pronounced compared to wt mice. TNFR1+/- heterozygous mice even had a stronger 
suppression of Dbp and Rev-Erb and a stronger induction of Bmal1 compared to TNFR1-/- 
mice. As was the case for TNFR1-/- and TNFR1+/-, also MyD88-/- and MyD88+/- differed in the 
response to CD40 ligation, suppression of Dbp and Rev-Erb and increase in Bmal1 being 
more pronounced in heterozygous mice (Fig. 5). 
 
 
Figure 5. MyD88-/- and TNFR1-/- mice are less prone to CD40 mAb induced dysregulation of clock gene 
expression. Gene expression in liver of mice held in a 12-h light/12-h dark cycle and sacrificed 2 days after i.p. 
injection of Ig2a (white bars) or CD40 mAb (gray bars) at ZT = 9-10 (ZT = 0, light on, ZT = 12, light off), 
quantified by RT-PCR. Besides of TNFR1-/- and Myd88-/- mice also their heterozygous littermates were analysed 
(+/-). Data are means + s.e.m. *P< 0.05, **P< 0.005, ***P< 0.0005, Mann-Whitney test. Data are from wt 
(IgG2a), n = 10; wt (CD40), n = 12; IL-6-/- (IgG2a), n = 9; IL6-/- (CD40), n = 11; TNFRI-/- (IgG2a), n = 10; 
TNFR1-/- (CD40), n = 11; TNFR1+/- (CD40), n = 6; IL-1R1-/- (IgG2a), n = 11; IL-1R1-/- (CD40), n = 11; MyD88-/- 
(IgG2a), n = 8; MyD88-/- (CD40), n = 10; MyD88+/- (CD40), n = 6. 
 32
To validate the importance of TNF:TNFR1 interaction in CD40-mediated alterations of 
expression of clock genes, we investigated the effect of CD40 ligation on DBP, REV-ERB 
and BMAL1 at the protein level (Supplementary Fig. 7). Treatment of wt mice, with CD40 
mAb was followed by significant downregulation of DBP and REV-ERB in nuclear extracts 
of livers at ZT9 day two post injection. The NF-B subunit p65, which is translocated to the 
nucleus upon immune activation, is upregulated. BMAL1 and CLOCK were unaffected. In 
TNFR1-/- mice only REV-ERB was significantly downregulated, but significance was less 
than in wt. NF-B showed a trend to upregulation. By comparing TNFR1-/- with TNFR1+/- 
mice both treated with CD40 mAb, we detected differences in DBP, REV-ERB, and 
BMAL1 expression, which was significantly decreased in heterozygous mice compared to 
monozygous TNFR1 knockout mice; no differences were seen for p65 and CLOCK. To 
evaluate the effect of CD40 mAb treatment on chromatin remodelling and the binding status 
of the transcription factors CLOCK and BMAL1 at the E-box sequences of the Dbp and Rev-
Erb promoters we established chromatin immunoprecipitation (ChIP) assays. Histone H3 
acetylation at Lys9 (AcH3K9) has been reported to be rhythmic in the Per1 and Per2, and the 
Dbp gene [103] being highest at ZT9 when transcriptional activity is at its maximum. In 
addition, rhythmic CLOCK:BMAL1 binding to the Dbp gene has been shown in detail. In 
CD40-treated wt mice, reduced levels of AcH3K9 were measured at the E-boxes of the Dbp 
and Rev-Erb genes (Fig. 6). CD40-treated wt mice, reduced levels of AcH3K9 were 
measured at the E-boxes of the Dbp and Rev-Erb genes (Fig. 6).  
Significant reduction of Bmal1 binding to E-box 2 of the Dbp and Rev-Erb gene was only 
observed in wt but not in TNFR1-/- mice. Thus the reduced transcription of Dbp and Rev-Erb 
is accompanied by reduced H3 histone acetylation and reduced CLOCK:BMAL1 binding at 
these sites.  
In the experiments reported above, CD40 ligation induces SBS and leads to dysregulation of 
the expression of clock genes. Deletion of Dbp reduces locomotor activity [75], alters period 
length [74], and reduces consolidation of sleep episodes after sleep deprivation [75]. 
Therefore, we analyzed whether the extent of CD40 mAb-induced reduction of locomotor 
activity correlates with altered clock gene expression in the different knockout mice. As 
shown in Figure 7, the extent of Dbp suppression correlates significantly with impairment of 
CD40 mAb-mediated suppression of locomotor activity.  
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Figure 6. CD40 ligation leads to chromatin modifications and impairsCLOCK:BMAL1 binding to E-
boxes of Dbp and Rev-Erbα. Chromatin immunoprecipitation was performed with antibodies against BMAL1, 
CLOCK, acetylated histone H3 lysine9 (acH3K9), and rabbit IgG. A) Schematic representation of the Dbp gene 
with E-boxes (blue), exons (red), and the quantitative PCR (qPCR) reactions. Note that pPCR 1 covers E-box 2 
which has been shown to rhythmically bind CLOCK:BMAL1 complexes [103]. QPCR 2 is located in exon 4 and 
has no E-boxes, which serves as control. Upper panels show values of wt, lower panels of TNFR1-/- mice. Black 
bars show isotype treated, gray bars show CD40 mAb treated animals (3 mice per group). Note reduced levels of 
BMAL1, CLOCK and acH3K9 abundance in wt and alleviated reductions in TNFR1-/-. B) Schematic 
representation of the Rev-Erbα gene similar to A. QPCR 3 is located near E-box 2 and qPCR 4 in exon 5. As 
seen with Dbp reductions of Bmal1, Clock and acH3K9 were less pronounced in TNFR1-/-. Mean + s.e.m. 
Student’s t-test. *P< 0.05. 
 34
Treatment with CD40 mAb leads to profound increase of the number of rest periods, in 
reduction of locomotor activity and repression of Dbp transcription in wt and IL-6-/- mice. 
These effects were only moderate in IL-1R1-/- mice as well as in heterozygous TNFRI+/- and 
MyD88+/- mice. Interestingly, the CD40 mAb-induced effects were not seen at all in TNFR1-/- 
and Myd88-/- mice. These findings indicate that CD40 ligation-mediated dysregulation of Dbp 
may be linked to the development of SBS. A trend in the same direction was also seen when 
correlating locomotor activity with the expression of Rev-Erb, though without reaching 
significance. Since the latter is well known to negatively regulate the expression of Bmal1 
[101], it is interesting that the correlation of locomotor activity and Bmal1 is found here to 
tend in the opposite direction compared to Rev-Erb.  
            
 
Figure 7. Suppression of Dbp gene expression correlates with 
the degree of CD40 mAb induced locomotor activity 
impairment. Pearson correlations between clock gene expression 
levels in liver and running wheel activity in the 12-h dark period of 
different gene knockout mice treated with CD40 mAb. Reduction in 
the expression of Dbp positively correlates with reduction in 
locomotor activity: R2 = 0.74, P = 0.01; Rev-Erbα: R2 = 0.43, P = 
0.1. Reduction in the expression of Bmal1 negatively correlates 
with reduction in locomotor activity R2 = 0.54, P = 0.059. Data are 
from wt (IgG2a), n = 10; wt (CD40),  n = 12; IL-6-/- (IgG2a), n = 9; 
IL6-/-(CD40), n = 11; TNFRI-/- (IgG2a), n = 10; TNFR1-/- (CD40), n 
= 11; TNFR1+/- (CD40), n = 6; IL-1R1-/- (IgG2a), n = 11; IL-1R1-/- 
(CD40), n = 11; MyD88-/- (IgG2a), n = 8; MyD88-/- (CD40), n = 10; 
MyD88+/- (CD40), n = 6. 
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DISCUSSION 
Here we found that ligation of CD40 leads to a pronounced impairment of locomotor activity 
and increased rest periods in mice at night, the time period the animals are usually active. 
Since this effect is not seen in TNFR1 deficient mice, TNF is the likely mediator of the 
behavioural changes. This is further substantiated by the observation that TNF injections in 
MyD88-/- mimic the effect of CD40 mAb and even revoke their resistance to develop SBS 
mice in response to CD40 mAb treatment. TNF serum concentrations in CD40 mAb treated 
MyD88 -/- mice were significantly lower compared to wt controls. Recent studies show that in 
MyD88-/-, the response to TLR agonists is abolished and TNF production induced by IL-1 is 
severely diminished [104]. Ligation of CD40 and subsequent binding to tumour necrosis 
factor receptor – associated factors (TRAF) leads to MyD88-independent signalling pathways 
including NF-B with subsequent up-regulation of proinflammatory cytokines such as 
TNFIL-1 and IL-6 (for review see [96]). CD40 ligation-induced SBS depends on TNFR1, 
but neither on IL-1R1 nor IL-6. TNFR1 has also been reported to mediate SBS in mice treated 
with TNF, the effects being dependent on the TNFR1 adaptor protein FAN [105]. TLR-
mediated SBS induced by LPS, as measured by immobility, social exploration, and body 
weight changes, still occurred in IL-1R1-/- mice or in mice treated with neutralizing antibodies 
to IL-1, IL-6 and TNF [35, 106]. Furthermore, administration of TNF blockers failed to 
prevent LPS-induced SBS [107]. Taken collectively TNF in TLR-mediated SBS seems of less 
importance, the TNF:TNFRI interactions, however, are crucial in CD40 ligation-induced 
SBS. Since CD40 mAb-induced impairment of locomotor activity is less pronounced in IL-
1RI-/- mice compared to wt mice, IL-1 is apparently less relevant than TNF to induce SBS.  
In the treatment of lymphoma, chronic lymphatic leukemia and multiple myeloma, the most 
common adverse event of humanized, agonistic CD40 mAb (Dacetuzumab) or of CD40L 
expressed by a replication-deficient adenovirus, is fatigue, which developed in up to 50% of 
the patients [99, 108-110]. In patients with solid tumours, CD40 mAb led to a pronounced 
increase of IL-6 and TNFin serum [111].A more direct link between TNF and fatigue has 
been provided in older studies trying to treat cancer patients with TNF Infusions of TNF 
induced a state of lethargy and severe fatigue and anorexia [112-113].  
Ligation of CD40 on antigen presenting cells (APC), including dendritic cells and monocytes, 
is important in stimulating expression of costimulatory molecules (CD80 and CD86) and 
production of TNF, IL-1IL6, IL-8, and IL-12 as well as in the rescue of circulating 
monocytes from apoptotic death (for review see [96]). CD40 ligation in-vivo induces an 
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inflammatory response in the lungs secondary to activation of bone-marrow-derived CD40 
positive cells [114]. CD40 mAb also trigger liver inflammation which is mediated by IFN 
and TNF [115]. Our data show that mice treated with CD40 mAb develop splenomegaly and 
loose significant weight. The increase in spleen size was seen in wt, IL-1R1-/- and IL-6-/- mice 
and even developed in MyD88-/- and TNFR1-/- mice, which nevertheless, are resistant to CD40 
mAb-induced SBS. 
However TNFR1-/- mice, and even more so MyD88-/- mice, appear to be protected from CD40 
mAb-induced weight loss. TNF is a catabolic cytokine. Transplantation of Chinese transgenic 
hamster ovary cells expressing the human TNF developed cachexia, with progressive wasting, 
anorexia, and early death [27]. TNFR1-/- mice injected with lung carcinoma cells showed 
reduced wasting compared to wt control mice, despite there being equal levels of serum TNF 
in both groups [116]. In experimental sepsis and tumour models chronic low level of TNF 
production results in sustained wasting and promotes insulin resistance [117-118]. In 
rheumatoid arthritis 67% of patients are diagnosed as having rheumatoid cachexia [119]. The 
TNF blocker Etanercept induced weight gain in at least some patients, the effect not being 
confirmed in another study [120-121]. Though, other factors such as IL-1 and IL-18 may 
contribute to rheumatoid cachexia. As seen with TNF also IL-1 administration promotes 
anorexia [122] and IL-18 has been found to modulate food intake and metabolism [123]. 
Unlike TNFR1-/- and MyD88-/- mice, IL-6-/- mice respond to CD40 mAb with pronounced 
weight loss. This contrasts with TLR-mediated changes in body weight, which after LPS 
injection was more pronounced in wt compared to IL-6-/- mice [21]. 
The circadian control of rest / activity cycles is provided by the hypothalamic suprachiasmatic 
nuclei which, by paracrine signalling, regulate circadian cycles of gene expression in every 
cell [65]. Administration of TNF alters the expression of clock genes, the genes which 
modulate circadian activity in the SCN and peripheral cells [92]. As reported for TNF, CD40 
mAb also lead to suppression of Period and Rev-Erb genes and of the clock-controlled 
genes Dbp, Tef and Hlf. The CD40 ligation-induced interference with Rev-erb expression is 
paralleled by upregulation of Bmal1. This may be the consequence of the physiological role of 
REV-ERB to bind to RORE DNA sequences in the Bmal1 promoter and thereby to inhibit 
transcription of the Bmal1 gene. As true for CD40 mAb-mediated impairment of locomotor 
activity with increased rest periods, also the CD40 ligation-induced dysregulation of clock 
gene expression depends on TNFR1, but not on IL-6 or IL-1R1. Recently, TNF was found to 
attenuate transcription of clock genes in mouse embryonic fibroblasts by interfering with the 
enhancing effects of DNA E-box sequences [92]. The data presented here substantiate this 
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finding by showing impaired BMAL1 binding to E-boxes in the respective Dbp and Rev-Erb 
promoters at ZT9, the effect being seen only in nuclear liver extracts obtained from CD40 
mAb treated wt, but not when derived from TNFR1-/- mice exposed to CD40 mAb. In 
addition, rhythmic histone acetylation underlies active or inactive transcription of clock genes 
[69]. Histones H3 are found acetylated at lysine 9 (AcH3K9) during high transcriptional 
activity and deacetylated during inactive transcription [103]. CD40 treatment lowered only 
the levels of AcH3K9 at the E-boxes of Dbp and Rev-Erb in liver samples from wt mice, but 
not from TNFR1-/- mice. Thus transcriptional clock gene deactivation by CD40 as judged by 
acetylated H3 is dependent on TNF signalling. Given the link between the clock and 
metabolism, the alterations in the molecular clock described above may altogether contribute 
to the vast changes of metabolic and physiologic parameters as seen in SBS [9, 124]. 
TNF:TNFR1 interactions in CD40 mAb treated mice lead to increased rest periods and altered 
clock gene responses. These two TNF evoked responses may in fact be linked to each other. 
Deletions of clock genes in mice lead to altered stability, amplitude and / or period length of 
activity cycles (Supplementary Table 1). Thus we looked for correlations in the extent of 
CD40 mAb-triggered impairment of locomotor activity and dysregulation of clock genes in 
the different knockout mice studied. Mice with the most dramatic CD40 mAb-induced 
increase in rest periods (wt and IL-6-/- mice) also showed the most pronounced decrease of 
Dbp expression. Concordance of the two phenomena is also seen in heterozygous TNFR1+/- 
and MyD88+/- mice as well as in IL-1R1-/- mice, both effects being less pronounced. TNFR1-/- 
and Myd88-/- mice were resistant to CD40 mAb-induced behaviour changes and Dbp 
suppression.  
In conclusion, we have demonstrated that following CD40 ligation TNF:TNFR1 interactions 
lead to SBS, which may result from dysregulation of clock genes. Identification of the 
mechanisms which hinder efficient activation of E-box mediated transcription of clock genes 
following TNF:TNFR1 interactions are expected to facilitate understanding of SBS in 
autoimmune diseases.   
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METHODS 
Material. Recombinant murine (rm) TNF-α was purchased from Peprotech (London, U.K.). 
The following antibodies (Abs) were used for ChIP assays: polyclonal antibodies for BMAL1 
and CLOCK were prepared from immunized rabbit sera as described [125]; polyclonal 
acetylated histone H3K9 (ab4441) and rabbit control IgG (ab46540) were purchased from 
Abcam, Cambridge, UK. For Westerns we used Abs: BMAL1, CLOCK, DBP (clone 3A6; 
Abnova, Taiwan), REV-ERB (#2124; Cell Signaling, Danvers, MA, USA), NF-B p65 (sc-
372; SantaCruz, CA, USA) and U2AF65 (U4758; Sigma, Saint-Louis, MO, USA). 
Mice. C57BL/6J mice were purchased from RCC Ltd (Füllinsdorf, Switzerland). 
Tnfrsf1atm1Blt termed TNFR1-/- mice were generously provided by Prof. Mathias 
Heikenwälder, Univ. Zurich, Switzerland; Il6tm1Kopf termed IL-6-/- mice by Prof. Pierre-Alain 
Clavien, University Hospital Zurich; Il1r1tmImx/J termed IL-1R1-/- by Prof. Manfred Kopf, ETH 
Zurich; MyD88tm1Aki termed Myd88-/- by Dr. Barbara Stecher, ETH Zurich. All strains have 
been backcrossed to C57BL/6J mice for at least 10 generations. For all experiments we used 
male mice aged between 8-12 wks. Animals were maintained under specific pathogen–free 
conditions. Experiments conformed to the guidelines of the Swiss Animal Protection Law and 
approved by the Veterinary office of Canton Zurich. Mouse experiments were performed 
under licenses 55/2008 according to the regulations of the Veterinary office of the Canton 
Zurich. 
Locomotor activity recording. Locomotor activity was recorded as previously described 
[92]. Shortly, mice were housed in individual cages, equipped with a running wheel and a 
passive infrared sensor in a temperature-controlled sound-proof light-tight room 
(approximately 22°C) with food and water ad libitium. Activity recordings were based on 1 
min episodes by using the Chronobiology Kit software (Stanford Software Systems, Santa 
Cruz, CA). Rest episodes were defined as 1 min units with zero activity. We allowed mice 10-
15 days of adaptation to the light-dark cycle (light on at 0500 = ZT0; light off at 1700 = 
ZT12). Mice were injected i.p. at ZT5 with 200 μg anti-CD40 antibodies (clone FGK4.5 ; 
 39
<0.61 EU/mg (LAL), BioX Cell, West Lebanon, NH, USA) in 200 μl PBS or 200 μg rat 
IgG2a (clone 2A3; <0.23 EU/mg (LAL), BioX cell) in 200 μl PBS. Two days after injection 
mice were weighted and killed at ZT 9-10. Tissues were excised and frozen until subsequent 
RNA extraction, or used fresh for liver nuclei isolation. 
Implantation of osmotic minipumps. Osmotic minipumps were implanted on the back of 
the mice as described before [92]. Briefly, Alzet minipumps (Model 1007D; Alzet, Cupertino, 
CA) filled with TNF-α (1.5 μg/day, diluted in 0.1% BSA/PBS) or 0.1%BSA/PBS as a control 
were inserted below the skin on the back. Locomotor activity was recorded as described 
above. Three days after minipump insertion mice were sacrificed and organs were processed 
for blood or qPCR analysis. 
RNA isolation and gene expression analysis. Mouse tissues were homogenized in 
peqGOLD RNA pure (PeqLab, Erlangen, Germany) and the RNA was extracted according to 
the manufacturer’s instructions. Isolated RNA was DNA digested and purified with spin 
columns NucleoSpin RNA II (Macherey-Nagel, Düren, Germany). Then cDNA was 
synthesized using random hexamers (Applied Biosystems, AB, Rotkreuz, Switzerland) and 
M-MuLV reverse transcriptase (AB). The cDNA equivalent to 20 ng of total RNA was PCR-
amplified in an ABI PRISM HT7900 detection system (AB) using the TaqMan Universal 
PCR Master Mix (AB) and quantified as previously described [126]. All samples were run in 
duplicate and results were normalized to 18S rRNA (AB). Relative mRNA levels are 
expressed as x-fold variations compared with the control treated group or as percent 
expression with the highest expressor set to 100 % in Fig. 4 and Supplementary Fig 6. 
Chromatin Immunoprecipitations (ChIP). ChIP assays were performed according to 
Ripperger et al [103]. The DNA was isolated using the iPure kit (Diagenode) based on 
magnetic DNA purification. The efficiency of ChIP of the loci analyzed were calculated from 
qPCR data and reported as a percentage of starting material: % (ChIP / total input) = 2 ^ 
((CtInput - (LOG(50;2)) - CtChIP) * 100.  Primers for genomic loci were as follows. QPCR1 
(mDbpI1), forward and reverse primers: 5'-ATGCTCACACGGTGCAGACA-3' and 5'-
CTGCTCAGGCACATTCCTCAT-3', probe: 5'FAM-CCTAGTTTCCATGTGACCCTGC 
GAGG- 3'BHQ1. QPCR2 (mDbpE4), forward and reverse primers: 5'-AAGAACAATGAAG 
CAGCCAAGAG-3' and 5'-GGCAGCCCGCACAGATAT-3', probe: 5'FAM-TGGTTCTCC 
TTGAGTCTTCTTGCATCTCTCG-3'BHQ1. QPCR3 (mRev5'U), forward and reverse 
primers: 5'-CCCACCCCAGTCCACTTTC-3' and 5'-GCCTATT CCTTTTCTGCTTTGC-3', 
probe: 5'FAM-CTCCTCCCCGCTGCCAGCAA-3'BHQ1. QPCR4 (mRevE5), forward and 
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reverse primers: 5'-TCTTCACCTATGCCCATGACAA-3' and 5' GACGGGCATCC CTGA 
CTCT-3', probe: 5'FAM-TGCCAATCATGCAT CAGGTAGCCCTT-3'BHQ1. 
Western blot from liver nuclei. Liver nuclei were isolated as for the ChIP assay without 
adding of formaldehyde. Nuclei were resuspended in NUN buffer (600 mM NaCl, 2 M urea, 
2% NP-40, 50 mM Hepes-pH7.6, 2 mM DTT) and the protein concentration from the cleared 
lysate was measured by BCA assay (Perbio). 20 µg protein was run on a SDS gel (4-20%, 
Novex, Invitrogen) and blotted afterwards on PDVF filter. The blots were blocked with 5% 
skim milk in TBS-T, and incubated in the same buffer with antibodies overnight at 4°C. After 
staining with secondary antibodies the blots were developed with ECLplus (GEhealthcare, 
Glattbrugg, Switzerland) and exposed in a ImageQuant 350 imaging system (GEhealthcare) 
by using the appropriate quantitation software.  
Elisa and Luminex. Blood was collected in Microtainer SST tubes (BD, Franklin Lakes, NJ, 
USA) and blood serum was obtained after short centrifugation. Sera were analyzed by 
luminex technology at Cytolab, Dällikon, Switzerland, or by conventional ELISA for IL-1 
(Invitrogen) 
Statistical analysis. The comparison of running wheel and infrared activity between anti-
CD40 and control treated animals was performed by two-way analysis of variance (ANOVA) 
with factor ‘interval’ and ‘treatment’. Whenever significant effects were present (P≤0.05) 
two-tailed paired t-tests were used to further evaluate differences. SAS (SAS Institute, Inc., 
Cary, NC, USA) and MATLAB (The Math Works, Inc., Natick, MA) were used for statistical 
analysis. 
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SUPPORTING INFORMATION 
 
 
 
 
Supplementary Fig. 1. Intraperitoneal challenge with anti-CD40 does not affect locomotor activity in TNFRI-/- 
C57BL/6 mice. A) Infrared activity for the first day after i.p. injection of 200 µg CD40 mAb (red) or IgG2a as 
control (blue). Baselines are the mean of three days preceding injection of CD40 mAb (black) or IgG2a control 
(gray). Mean of 1-h values ± s.e.m. B) Difference in infrared activity after subtracting the baseline. Blue line: 
IgG2a; Red line: CD40 mAb. The data are shown as means ± s.e.m. Stars indicate 1-h interval which differed 
significantly between treated and baseline groups: *P<0.05, **P<0.005, ***P<0.0005, 2-tailed t-test after 
significant 2-way ANOVA for ‘interval’ and ‘treatment’.  
C) 24-h actograms of infrared activity of five representative mice after antibody injections. Each line represents 
one individual mouse, one day before (baseline, BL) and one day after injection of IgG2a and CD40 mAb. The 
light-dark period is indicated by the black and white bars at the top of the plot. Data are from wt (IgG2a), n = 10; 
wt(CD40 mAb),  n = 12; IL-6-/- (IgG2a), n = 9; IL6-/- (CD40 mAb), n = 11; TNFRI-/- (IgG2a), n = 10; TNFR1-/- 
(CD40 mAb), n = 11;  IL-1R1-/- (IgG2a), n = 11; IL-1R1-/- (CD40 mAb), n = 11; for A and B. 
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Supplementary Fig. 2. Running distance in the dark period prior to IgG2a and CD40 mAb treatment are shown 
in light and dark gray bars resp. and 24 hr after injection of IgG2a (blue bars) and CD40 mAb (red bars). 
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Supplementary Fig. 3. Mice treated with CD40 mAb show increased long rest epochs in the dark phase. 
Analysis of rest epochs for the 12-hr dark period one day after injection of IgG2a (white bars) or CD40 mAb 
(grey bars). The data show the differences in numbers of 1-min episodes with activity = 0 after having subtracted 
the baseline (mean of the three days before injection). The occurrence of rest was arbitrarily subdivided in 
episodes for durations with rest = 0 activity counts: up to 1 min rest, between 2 and 5 min, 6 and 60 min, and 
more than 60 min. ANOVA for repeated measures, followed by independent-samples t-test: * P<0.05, ** 
P<0.005, *** P<0.0005. 
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Supplementary Fig. 4. Effect of CD40 ligation on locomotor activity of TNFRI+/- and MyD88+/- mice. Running 
wheel activity for the first day after i.p. injection of 200 µg CD40 mAb or IgG2a as control. A) Frequency of 
running wheel activity for the first day after i.p. injection of 200 µg CD40 mAb (red line) or IgG2a as control 
(blue line). Baselines are the mean of three days preceding injection of CD40 mAb (black line) or IgG2a control 
(gray line). Mean of 1-h values ± s.e.m. B) Difference in running wheel activity after subtracting the baseline. 
Blue line: IgG2a; Red line: CD40 mAb. The data are shown as means ± s.e.m. Stars indicate 1-h interval which 
differed significantly between treated and baseline groups: *P<0.05, **P<0.005, ***P<0.0005, 2-tailed t-test 
after significant 2-way ANOVA for ‘interval’ and ‘treatment’. C) Actograms show running wheel data from five 
representative mice after injection. Each line represents one individual mouse, one day before (baseline, BL) and 
1 day after injection (IgG2a and anti-CD40 resp.). The LD period is indicated by the black and white bars at the 
top of the plot. TNFRI+/-: n = 6; TNFRI-/-: n = 10; MyD88+/-: n = 6; TNFRI-/-: n = 10; MyD88-/-: n = 10. 
 
 
 
 
Supplementary Fig. 5. A) Low serum TNF concentrates in MyD88-/- mice. TNF was measured by ELISA in 
serum of wt or MyD88-/- two days after injection of CD40 mAb or IgG2a control antibodies. Means ± s.e.m. 
**P<0.005, Mann-Whitney test. B) Serum cytokine levels one day after anti-CD40 treatment or IgG2a measured 
by Luminex, TNF and IL-6, and ELISA IL-1β. 
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Supplementary Fig. 6. Circadian gene expression of clock and clock-controlled genes are impaired by anti-
CD40 treatment in the kidney. During a 24 h time period (one day p.i.) gene expression was quantified by qPCR 
for the respective genes (compared to 18s rRNA endogenous control and calibrated to the highest expressor, i.e. 
100% expression). Note induced levels of Bmal1 at ZT9, and profound reductions in the amplitude expressions 
of E-box dependent clock, i.e. Rev-Erb, Per2, Per3, and clock-controlled genes, i.e. Dbp, Hlf, and Tef. Three 
mice per time point and treatment group were analyzed. Mean ± s.e.m. 2-tailed Student’s t-test: *P<0.05, 
**P<0.005, ***P<0.0005. 
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Supplementary Fig. 7. The abundance of clock proteins in liver nuclear extracts is impaired by anti-CD40 and 
reveals differences between wt and TNFR1-/- mice. A) Western blots of different clock proteins from liver 
nuclear extracts from individual mice (each lane) with different tnfr1 genotypes (+/+, -/-, +/-). DBP (40 kDa), 
REV-ERB (82 kDa), BMAL1 (80 kDa), CLOCK (105 kDa), NF-B-p65 (65 kDa), and nuclear expressed 
U2AF65 (65 kDa) endogenous control were immunostained by conventional western blot technique. B) 
Densitometric quantification of western blots shown in A. The relative protein abundance is calculated by the 
ratio of the clock protein to endogenous control. Note significant downregulations of DBP and REV-ERB 
proteins and upregulation of p65 in anti-CD40 treated wt mice (left panels). In contrary, TNFR1-/- mice (middle 
panels) show less significant impairments of clock proteins. Significant differences in DBP, REV-ERB, and 
BMAL1 were also detectable when comparing anti-CD40 treated homozygous vs. heterozygous knockouts. 
downregulation of REV-ERBa and only minor changes a  from six different mice per treatment group. Left panel 
shows wt mice, middle panel TNFR1-/- mice, and right panel compares knockouts with heterozygous mice. 
Three mice per time point and treatment group were analyzed. Mean ± s.e.m. 2-tailed Student’s t-test: * P<0.05, 
** P<0.005, *** P<0.0005. 
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ABSTRACT 
Treatment of fibroblasts for 24 hours with tumour necrosis factor-alpha (TNF) suppresses 
transcription of E-box driven clock genes (Dbp, Tef, Hlf and Per1, Per2, Per3) by yet 
unknown molecular mechanisms. The attenuation of clock genes has been suggested as a 
putative cause for the development of sickness behaviour syndrome in infections and 
autoimmune diseases. Here, we studied the effect of TNF- at early time points (<3 h) on 
intracellular signalling events and clock gene expression in fibroblasts. Interaction of TNF 
with TNFR1 (Tnfrsf1a, CD120a, p55) leads to downregulation of gene expression of D-site 
albumin binding protein (Dbp) and upregulation of negative regulators of the molecular clock, 
Period-1 and -2 (Per1 and -2), Cryptochrome-1 (Cry1), and Differentiated embryo 
chondrocytes-1 (Dec1). Since the decrease of Dbp is also observed in knockout cells for 
Per1/2 and Dec1, these genes are unlikely to be responsible for inhibition of Dbp. The effect 
of TNF on the clock genes, Dbp and Per1, in the early phase is dependent on p38 mitogen 
activated protein kinase (MAPK) and/or calcium signalling but not on the activation of NF-
κB or AP-1. Taken collectively the data show p38 MAPK and calcium dependent, TNFR1 
mediated transient increase of negative regulators of the molecular clock and an independent 
decrease of Dbp. 
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INTRODUCTION 
TNF is a pleiotropic cytokine, which regulates the activation and function of a variety of cells 
including lymphocytes, fibroblasts and neurons [128]. Its receptors, especially TNFR1, are 
ubiquitously expressed [129]. In response to infections or in inflammation during autoimmune 
diseases (e.g. rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease) TNF 
is produced mainly by dendritic cells and macrophages [128]. While infusions of TNF in 
cancer patients lead to severe daytime fatigue [112], treatment of patients with rheumatoid 
arthritis or obstructive sleep apnoea syndrome with TNF blockers reduces disease-associated 
fatigue [130-131]. On the other hand, a disruption of the circadian clock can lead to the same 
symptoms. These data indicate a possible influence of TNF on the circadian system and 
thereby on fatigue. 
Recently, the effect of TNF on the molecular clock was investigated by our group. The data 
showed that TNF reduces the expression of E-box driven clock genes in cultured fibroblasts. 
Moreover TNF impairs nocturnal locomotor activity in mice, the effect being associated with 
a decrease of clock genes in the liver [92]. These results suggest that TNF, by interfering with 
clock gene expression, might attenuate the circadian output of physiological and behavioural 
rhythms. Here, we aimed to elucidate signalling events leading to reduced clock gene 
expression, in TNF treated fibroblasts. 
The molecular clock is the cellular basis of circadian rhythms found in almost every organism 
ranging from bacteria, plants, and flies to humans. Circadian rhythms control many aspects of 
physiology and metabolism that allow organisms to anticipate regular changes in the 
environment (for reviews see [64]). In mammals, the integration of the day and night variation 
is provided by the suprachiasmatic nucleus (SCN) of the hypothalamus, which receives light 
information from the retina and synchronizes the clock of other brain areas and peripheral 
organs. Rhythms in single cells are thought to origin from interlocked transcription-translation 
feedback loops composed of positive transcriptional activators Clock and Bmal1 and negative 
elements such as Per and Cry. CLOCK and BMAL1 heterodimerize and bind to E-box 
enhancer sequences to promote transcription of Per1, Per2, Cry1, and Cry2, the products of 
which inhibit the activity of CLOCK:BMAL1 and hence their own transcription. A second 
feedback loop controls the expression of the positive clock element: REV-ERBα - itself 
activated through E-boxes by CLOCK:BMAL1 - rhythmically inhibits Bmal1 transcription 
[132]. Post-translational modifications, such as phosphorylations, acetylations, sumoylations, 
among others allow for the fine tuning of the system generating a period of about 24 hours. 
Clock-controlled genes (CCGs) such as Per3 and the members of the PAR-bZip family of 
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transcription factors, Dbp, Tef, and Hlf, also bear E-box motifs and their periodical expression 
contributes to the transformation of time information into physiological and behavioural 
rhythms. However, they are not integral part of the timing system. 
TNF signals via two receptors: TNFR1 (p55TNFR, CD120a, TNFRSF1a) and TNFR2 
(p75TNFR, CD120b, TNFRSF1b). Whereas TNFR1 is ubiquitously expressed and more 
effective in sensing soluble TNF; TNFR2 has a higher affinity to the membrane bound 
cytokine, is involved in ligand passing to TNFR1 and bears its main functions in chronic 
inflammatory conditions. After receptor activation different intracellular adaptor proteins 
direct a complex array of signalling processes mediated by kinases, phosphatases, reactive 
oxygen intermediates, lipases, caspases, and sphingomyelinases. This leads to regulation of 
the cell function by transcription factors, G-protein signalling, and calcium ion signalling. In 
the TNF dependent intracellular signalling cascade, activation of caspases and the 
transcription factors NF-B and AP-1 are important steps and have been found to regulate 
apoptosis and expression of chemokines and cytokines.  
This study was aimed to characterize the relevant intermediates of TNF signalling leading to 
altered clock gene expression. In the early response of fibroblasts to TNF, transcription of 
negative clock gene regulators, namely Per1/2, Cry and Dec1 is activated. However, this 
induction is unlikely to be involved in downregulation of the clock-controlled gene Dbp. 
Impaired expression of Dbp was not dependent on caspase signalling, NF-κB, or AP-1 
activation, but rather on the calcium ion signalling. Although there is less binding of 
acetylated histone H3 to the Dbp E-box 857, active deacetylation is not involved in the 
inhibition of Dbp by TNF. 
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RESULTS 
Immediate early induction of negative clock elements parallels fast Dbp downregulation. 
To elucidate the direct effects of TNF on clock gene expression, we followed the immediate 
early response in NIH 3T3 fibroblasts. Upon treatment with TNF-, expression of the clock 
controlled gene Dbp started to decrease after 15 min and reached 20% of control after 2 h 
(Fig. 1A, top left). A more delayed downregulation was observed when analyzing the 
expression of Per3 (Fig. 1A bottom middle). In contrast, Per1 - and to a lower extent also 
Per2 - showed a significant transient peak of expression at 1 h after stimulation (Fig. 1A and 
B), with subsequent downregulation at later time points. Whereas both Cry1 and Dec1 were 
successively upregulated, the effect of TNF on Cry2 and Dec2 was less pronounced and the 
expression of Clock was hardly affected (Fig. 1A). The Per1 gene is regulated by two 
alternative promoters [133] regulating two alternative first exons, i.e. 1A and 1B.  
 
 
 
Fig. 1: Early expression time course of clock genes in TNF treated NIH 3T3 fibroblasts. (A) Cells were 
stimulated with 10 ng/ml TNF in serum-free medium and mRNA expression of clock genes was analyzed at the 
indicated time points. Shown is the mean ± SD from 1 experiment in triplicates out of 2. (B) Per1 and Per2 are 
significantly induced and Dbp significantly inhibited after 1 h stimulation with TNF-α. Shown is the mean + SD; 
n = 10 for Per1 and Dbp, n = 6 for Per2. (C) Induction of Per1 is mediated by promoter 1A and 1B. NIH 3T3 
were stimulated with 10 ng/ml TNF-α for 1 h; n = 3 in triplicates. Shown is the mean + SD. For B and C we used 
paired sample t-tests: *P< 0.05, **P< 0.005, ***P< 0.0005 
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There was no difference in the Per1 peak induction at 1 h at the different promoters indicating 
similar regulation of both promoters (Fig. 1C). Taken collectively, the data show that the 
clock genes analyzed respond differently to TNF treatment in a time dependent manner. 
In further experiments we tested if TNF induces increased degradation of Dbp mRNA. When 
blocking RNA transcription with Actinomycin D, no enhanced degradation of the short-lived 
Dbp mRNA was observed (Fig. S1A). However, we still found downregulation of pre-mRNA 
transcription by analysis of nascent transcripts (Fig. S1B). Hence, the effect of TNF to 
downregulate Dbp mRNA is due to a block in transcription and to the short lifespan of the 
mRNA. 
 
Cycloheximide partly de-represses Dbp inhibition 
To assess the dependency of Dbp downregulation on de-novo induced proteins, we performed 
assays with cycloheximide (CHX), a compound inhibiting protein biosynthesis. Five hours 
before TNF treatment, CHX was added to the cell cultures to inhibit protein translation. 
Thereafter, TNF was added only for 2 h because a longer exposure was found to induce 
apoptosis. The inhibition of Dbp expression was reversed but could not be de-repressed 
completely (Fig. 2).  
 
 
Fig. 2: The inhibition of Dbp is partly dependent on de-novo 
protein synthesis. After a 5 h pretreatment with cycloheximide (100 
µg/ml) NIH 3T3 fibroblasts were stimulated with TNF for 1 h. 
Expression of untreated samples corresponds to 1. Shown is the mean 
+ SD. n = 3 in triplicates; paired samples t-test: *P< 0.05, **P< 0.005. 
 
 
 
 
 
These results show that the downregulation of Dbp is partly dependent on de-novo protein 
synthesis e.g. of a short-lived protein, but cannot be fully explained by a newly produced 
putative inhibitor, a fact also supported by the fast kinetics of Dbp downregulation. 
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The transient induction of negative regulators by TNF is not involved in later Dbp 
repression 
Mammalian Per genes are necessary for the generation of proper circadian rhythm. The 
induction of Per1 which acts as a negative feedback regulator could be important for the long-
lasting TNF- mediated downregulation of clock genes. Increased Per gene expression could 
lead to increased PER levels with putatively enhanced stability and activity by 
posttranscriptional modifications. To evaluate this hypothesis, we analyzed mouse embryonic 
fibroblasts (MEFs) lacking Per1, Per2, or both of them [134]; those were compared to MEFs 
from corresponding wt mice. The baseline expression of the clock genes, Dbp, Clock, and 
Bmal1 is strongly reduced in Per1-/- and lower in Per2-/- MEFs. For unknown reasons the 
expression of Dbp in Per1/2-/- was not different compared to wt MEFs (Fig. 3A, left panel). 
However, in regard to the TNF- response it becomes clear that the ability of TNF to 
downregulate Dbp gene expression was still present in all genotypes when compared to 
baseline levels (Fig. 3A, right panel). Only a moderate loss of effect of TNF was seen in Per1-
/- and Per2-/- MEFs cells, which however was not seen in double mutant cells. A faint 
upregulation of Clock and Bmal1 was observed in all genotypes upon TNF challenge (Fig. 3A 
right panel). In conclusion, the mutations of Per genes had no major impact on the effects of 
TNF on the clock genes analyzed. 
We also analyzed whether the TNF induced increase of Dec1 (Stra13/Sharp2/BHLHB2) is 
responsible for downregulation of Dbp (Fig 1A). This possibility rose because of recent data 
on DEC1 to impair E-box mediated transcription [135]. Our data show that TNF effectively 
repressed Dbp gene transcription also in the human keratinocyte cell line, HaCaT. However, 
this effect was not de-repressed in Dec1-deficent HaCaT cells which have a targeted 
inactivation of Dec1 on both alleles through homologous recombination (Fig. 3B) [136]. 
Taken collectively, our data show that despite of being upregulated at early time points 
neither PER1 and PER2 nor DEC1 seem to act as Dbp repressor molecules in TNF- treated 
cells. 
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Fig. 3: The transient induction of negative clock regulators by TNF is not responsible for the repression of 
Dbp. (A) Dbp expression is repressed in wt, Per1, Per2 or Per1/2 double mutant MEFs, whereas the expression 
of the central clock genes Clock and Bmal1 remains unchanged. Cells were stimulated with 10 ng/ml TNF for 6 
h. Shown is the mean + SD; left panel shows 1 representative experiment done in triplicates where the gene 
expression in wt untreated cells is set to 1; right panel is the mean of 3 independent experiments done in 
triplicates, where 1 represents the relative expression in the corresponding not TNF treated MEFs. (B) Dbp 
inhibition is independent of the presence of DEC1. Human keratinocytes, HaCaT cells, lacking the Dec1 gene 
were treated with 10 ng/ml TNF for 4 h. Shown is the relative expression compared to untreated cells. Bars 
represent mean + SD. n = 3 in triplicates. For A and B we used paired samples t-test: *P< 0.05, **P< 0.005, 
***P< 0.0005. 
 
Signalling via TNFR1 leads to the Per1 peak and Dbp downregulation independent of 
NF-κB, AP-1 or caspase activation 
To analyze the dependency of TNF receptors on the clock gene responses - i.e. Dbp 
downregulation and Per1 peak - we generated cells from TNFR1-/-, TNFR2-/-, and wt mice. 
Using RT-PCR, TNFR1 mRNA expression was found to be abolished in TNFR1-/- but still 
present in TNFR2-/- MEFs. TNFR2 mRNA expression is detected in both knockout 
genotypes, because the tnfr2 deletion is situated outside of the amplified sequence (Fig. 4A). 
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However, cell surface receptor expression is completely abolished in the respective knockouts 
(Fig. 4B). After 1 h TNF stimulation, the Per1 peak could be detected in wt MEFs similar, 
although to a lower extent than in NIH 3T3 cells. A Per1 peak was also seen in TNFR2-/-, but 
not anymore in the TNFR1-/- MEFs (Fig. 4C, left panel). To assay the downregulation of 
clock-controlled genes we looked at a later time point (6h), where inhibition is complete for 
all genes usually affected [92]. Dbp and Per3 were downregulated in wt and TNFR2-/-, but not 
in the TNFR1-/- MEFs, whereas Clock and Per1 were unaffected in all genotypes (Fig. 4C, 
right panel). However, it is to note that, for unknown reasons, Per1 was not downregulated in 
wt MEFs which is in contrast to the strong inhibition seen in NIH 3T3 cells. Our data show 
that both the TNF induced Per1 peak at early time points and the inhibition of Dbp is 
mediated by TNFR1. 
The major signalling pathway induced by TNFR1 leads to the activation of NF-κB 
transcription factor by its deliberation from the complex with the inhibitor of κB (IκB) 
proteins and subsequent translocation to the nucleus. The NF-κB transcription factor is 
composed mainly of the dimerized partners p65 and p50, transcriptional activity being strictly 
dependent on p65. Targeted inactivation of the RelA (p65) subunit of NF-κB in mice showed 
embryonic lethality due to massive liver apoptosis [137]. The lethal phenotype could be 
reversed by breeding the mice in TNF deficient animals [138]. Here, we analyzed p65-/- MEFs 
compared to wt control MEFs of the same genotype. As expected in western blot of p65, p65-
/- clearly distinguish from wt MEFs (Fig. 5A, left panel). Further, we analyzed the capability 
of these cells to activate a 4x-κB site element luciferase reporter gene and IL-6 induction. The 
p65-/- MEFs had lower luciferase baseline levels and were not able to induce NF-κB after 
short TNF treatment (data not shown). In addition, p65-/- MEFs lacked the ability to respond 
to TNF by inducing IL-6 mRNA (Fig. 5A, right panel). Since TNF treatment in p65-/- MEFs 
leads to apoptosis starting around 4 h we analyzed the effects at time points 1 h (Per1 peak) 
and 4 h (Dbp repression). In p65-/- MEFs TNF still induced the Per1 peak and repressed Dbp 
expression (Fig. 5B). This observation is supported by lack of effect on Dbp inhibition when 
adding wedelolactone (data not shown). This compound inhibits NF-κB-mediated gene 
transcription by blocking the phosphorylation and degradation of IκB. 
In addition to NF-κB activation, we also used an inhibitor to the c-jun N-terminal kinase 
(JNK), which phosphorylates c-Jun. Together with c-Fos, c-Jun forms the transcription factor 
AP-1. Again, early effects on Per1 peak and Dbp repression at 1 h were unaffected by the 
inhibition (Fig. 5C). The same holds true for inhibition of caspases with a pan-caspase 
inhibitor (Fig. S2). 
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Fig. 4: TNFR1-dependent Per1 induction and Dbp repression. (A) RT-PCR of TNFR1 and TNFR2 in MEFs 
from wt (1), TNFR1-/- (2), TNFR2-/- (3), or peritoneal macrophages (4). (B) Confirmation of cell surface 
expression of TNF receptors by FACS. B16 murine melanoma cells, wt, TNFR1-/-, TNFR2-/- MEFs were used 
for FACS staining with isotype (grey), TNFR1 (red line), and TNFR2 (green line) antibodies. (C) Different 
genotype MEFs were treated with 10 ng/ml TNF in serum-free medium for 6 h (left panel) or 1 h (right panel). 
Shown is the mean + SD. n = 3 (left panel) or n = 4 (right panel) both in triplicates. Paired samples t-test: *P< 
0.05, **P< 0.005. 
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Fig. 5: The c-jun N-terminal kinase and p65 are not involved in the early effects of TNF on clock genes. 
(A) p65-/- MEFs do not express p65 and fail to induce IL-6 upon TNF stimulation. Left panel: wt or p65-/- MEFs 
were lysed and subjected to Western blot analysis. b-tubulin was used as a loading control. Right panel: wt or 
p65-/- MEFs were treated with 10 ng/ml TNF in serum-free medium for 4 h (Dbp panel) or 1 h (Per1 panel). 
Shown is the mean + SD; n = 4 in triplicates. There is no significant difference between wt and p65-/- MEFs. (C) 
A JNK inhibitor prevents neither the Per1 peak nor the Dbp repression. NIH 3T3 fibroblasts were pretreated 
with 1µM inhibitor for 1 h and then stimulated with 10 ng/ml TNF for another hour. 1 represents the expression 
level in untreated cells. n = 3 in triplicates. 
 
Per1 peak and Dbp inhibition induced by TNF are dependent on calcium ion signaling 
and activation of p38 MAPK 
Next we assessed the role of intracellular Ca2+ in the TNF induced clock gene response. As 
previously reported, we confirmed that calcium ionophores (ionomycin and PMA) induce 
Per1, but in addition we could also observe a downregulation of Dbp at the early phase (data 
not shown). To further confirm an involvement of intracellular Ca2+ signalling in the 
regulation mechanism, we used the intracellular calcium chelator BAPTA-AM. The addition 
of BAPTA-AM effectively reduced the Per1 peak after 1 h treatment of NIH 3T3 fibroblasts 
with TNF. Moreover, BAPTA-AM also effectively blocked the repression of Dbp. On the 
other hand ethylene glycol tetraacetic acid (EGTA), which chelates extracellular calcium and 
thereby inhibits influx of extracellular calcium, had only minor effects (Fig. 6A). Given these 
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results, we find TNF acting on clock gene expression by modulation of intracellular calcium. 
In the attempt to elucidate the implication of further TNF signalling enzymes, we tested 
several kinase and phoshatase inhibitors. However, blocking the protein phosphatases (PP) 1 
and PP2a or the kinases phosphoinositide-3-kinase, extracellular signal regulated kinase I and 
II, or calcium/calmodulin dependent kinase II had no influence on clock gene regulation by 
TNF. Solely, the inhibition of the MAPK p38 was able to prevent the Per1 peak (Fig. 6B). 
However Dbp expression inhibition was not affected. 
Taken together, the data suggests that Per1 induction by TNF is dependent on intracellular 
calcium and p38 signalling. 
 
 
Fig. 6: The inhibition of Dbp is mediated by intracellular Ca2+ and the induction of Per1 is mediated by 
intracellular Ca2+ and p38 MAPK. (A) Effect of the intracellular calcium chelator BAPTA-AM on Per1 
induction and Dbp inhibition by TNF. NIH 3T3 were treated with EGTA (1 µM) or BAPTA-AM (30 µM) 30 
min before a 1 h stimulation with 10 ng/ml TNF. Expression of untreated samples corresponds to 1. Shown is the 
mean + SD; n = 3-5 in triplicates; (B) Effect of p38 MAPK inhibition on the Per1 peak induced by TNF. NIH 
3T3 were treated with SB203580 (10 µM) 30 min before a 1 h stimulation with 10 ng/ml TNF. Expression of 
untreated samples corresponds to 1. Shown is the mean + SD. n = 4 in triplicates. For A and B we used paired 
samples t-test: *P< 0.05. 
 
Chromatin remodelling defines clock gene regulations 
To analyze the chromatin remodelling on the Dbp gene after TNF stimulation, we performed 
chromatin immunoprecipitation (ChIP) assays against acetylated histone H3. There is clearly 
less acetylated histone H3 at the Dbp E-box 857 corresponding to the less activity in gene 
transcription. Therefore, we aimed to block deacetylation by using Trichostatin A (TSA) 
(HDAC 2 und 3) or splitomicin (HDAC 1). We did not find any significant effects on the 
inhibition of Dbp by TNF using TSA or splitomicin. These results suggest that active 
deacetylation is not important for blocking gene transcription of clock genes. 
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Fig. 7: Less acetylated histone H3 at the Dbp E-box 857 corresponds to reduced expression, but active 
deacetylation is not involved in the inhibition of Dbp by TNF. (A) Less acetylated histones H3 at the Dbp E-
box 857 in cells treated with TNF assayed by ChIP. NIH 3T3 fibroblasts were synchronized by a serum shock 
and stimulated with 10 ng/ml TNF in serum-free medium. After 24 h, at the peak of Dbp gene expression, 
chromatin was isolated and subjected to ChIP assay. Shown is the relative binding of acetylated histones 
compared to unstimulated cells. n = 3 in duplicates or triplicates. (B) Trichostatin A and splitomicin have no 
effect on the inhibition of Dbp by TNF. After a 6 h or overnight pretreatment with TSA (10 ng/ml) or splitomicin 
(120 µM) NIH 3T3 fibroblasts were stimulated with 10 ng/ml TNF for 3 h. 1 is the expression level in mock 
treated cells. Shown is the mean + SD. n = 3 for TSA, n = 2 for splitomicin, both in triplicates; For A and B we 
used paired samples t-test: *P< 0.05. 
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DISCUSSION 
The biology of circadian rhythms in mammals is dependent on the appropriate function of the 
molecular clock within all cells of the body. The activation of the immune system parallels 
the deregulation of circadian functions during the acute phase of infectious and autoimmune 
diseases; it is therefore intriguing to speculate that this may be linked to the sickness 
behaviour syndrome. Recently, TNF was found to impair locomotor activity in mice and to 
impair E-box driven clock gene expression [92]. Fibroblasts treated for 24 h with TNF 
respond with a decrease of E-box mediated transcription of Dbp, Tef and Hlf and of Period 1-
3. The data on the effect of TNF on fibroblasts presented here show that TNF treatment for 
only 1 h induces Per1. This effect was not associated with synchronization of the fibroblasts 
(data not shown), although a striking characteristic of the synchronization of cells is the 
induction of the clock gene Per1 mRNA and protein. This may be a necessary event for the 
induction of circadian gene expression, but it is probably not sufficient as shown for 
epidermal growth factor which strongly induces Per1 but still does not induce circadian gene 
expression [139].  
Surprisingly, we found that besides Per1, TNF can also transiently induce other negative 
elements of the clock such as Per2, Cry1 and Dec1. Because blockade of de-novo protein 
synthesis partially reverses Dbp inhibition, the increase in negative regulators could be 
partially responsible for TNF mediated impairment of Dbp expression. However, when 
assaying Per1, Per2, and Dec1 deficient cells, we have not found direct evidence for this 
hypothesis. Dec1 and Dec2 have been reported to be regulated by several cytokines and Dec1 
is also induced by TNF in our in-vitro setting [140]. Even though we did not analyze the 
effect of Cry, there is indirect evidence that also Cry is not responsible for TNF induced 
downregulation of Dbp expression, because the heterodimerization of CRY:PER proteins 
should also be impaired in our Per deficient fibroblasts. Furthermore the induction of Cry1 
expression appears fairly late when Dbp is already strongly inhibited. These data strongly 
suggest that neither Per1 and Per2, nor Dec1 and Cry1 are involved in Dbp repression. 
However, it still cannot be excluded that in Per1/Per2 double knockout cells Dec1 may lead 
to suppression of Dbp expression. Moreover, Per1 and Per2 may compensate for Dec1 
deletion. 
TNF mediates its function by TNF receptors, TNFR1 and TNFR2. By using knockout 
fibroblasts, we observed that signalling via TNFR1 is sufficient to detect the early Per1 
upregulation and early as well as late Dbp downregulation. There are evidences that soluble 
murine TNF has a higher affinity to TNFR1, and that ligand binding to TNFR2 is short and 
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unstable [141]. We detected no cell activation by measuring IL-6 expression in TNFR1 
deficient cells, still expressing TNFR2 on the surface, indeed emphasizing the higher relation 
of soluble TNF to TNFR1. We were surprised to find that the main TNF signalling pathways, 
comprising the NF-κB, JNK and caspase pathways are not responsible for clock gene 
regulation and that rather a “side” pathway, the Ca2+ signalling, is mediating the E-box 
dependent effect of TNF. A role for calcium signalling in circadian clocks has been 
extensively studied in the SCN. There it has been shown that not only Ca2+ can regulate clock 
gene expression but also that the circadian clock controls intracellular Ca2+ rhythms [142-
144]. Ca2+ influx is an initial cellular event in response to glutamate stimulation by the 
retinohypothalamic tract in the SCN, thereby disturbing the intracellular Ca2+ homeostasis. It 
has therefore been proposed to be one of the messengers conveying environmental time 
signals to the endogenous clock. The Per1 gene is first induced before it is inhibited at later 
time points. This induction is dependent on the activation of p38 and intracellular Ca2+. These 
to messengers are well described to lead to a phosphorylation of the cAMP responsive 
element (CRE) binding protein (CREB). In the SCN, the binding of CREB to CRE sites in the 
Per1 promoter in turn induces gene expression [145-146]. Although it remains to be further 
investigated, we think that Per1 expression is first induced through its CRE sites and 
thereafter inhibited through its E-box sequences. Here, we report the novel finding of clock 
gene expression regulation by Ca2+ signalling outside of the SCN. It therefore seems that Ca2+ 
plays a central role in the periphery as well. We think that analogue to the SCN, Ca2+ could 
also be considered as a physiological sensor in the periphery, transmitting immunological 
changes to the molecular clock and thereby coordinating the special needs to specific time 
windows. 
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MATERIAL AND METHODS 
Cell lines, cytokines and chemicals. Murine fibroblast cells, NIH 3T3 (CRL-1658) were 
obtained by the American Type Culture Collection; human keratinocyte cells, HaCaT, 
knockout for Dec1, were generously provided by B. Vogelstein [147]. Embryos of wt 
(C57Bl/6), TNFR1-/-, TNFR2-/- mice were used at day 12 of gestation (E12). The liver and 
heads were removed and the remaining tissue was digested with 0.25% trypsin-EDTA in 
DMEM for 30 min at room temperature. The dissociated cells were plated in DMEM 
containing 20% FCS. They were split 1:4 until they reached passage 10. Cells were used 
within passage 10 - 30. p65-/- and control MEFs were generously provided by M. Hottiger 
(University of Zürich) [148]. mPer1-/- and mPer2-/- single knockout and mPer1-/-;mPer2-/- 
double knockout MEFs were generously provided by U. Albrecht (University of Fribourg) 
[134]. 
Recombinant murine (rm) TNF, was purchased from Peprotech (London, U.K.); BAPTA-
AM, Cycloheximide, EGTA, splitomicin, actinomycin D from Sigma (ST.Louis, MO, USA); 
SB203580 from EMD chemicals (Darmstadt, Germany) and Trichostatin A from InvivoGen 
(St. Diego, USA). 
Cell culture and stimulation. NIH 3T3 fibroblasts were grown in DMEM (Gibco, Basel, 
Switzerland) supplemented with 10% FBS (PAA Laboratories, Pasching, Austria) and 
Glutamax (Gibco). For stimulation cells were grown to confluency and then medium was 
replaced with serum-free DMEM/Glutamax with or without TNF. After stimulation, tissue 
culture plates were washed once with ice-cold PBS solution and kept at –70 °C until the 
extraction of whole-cell RNA. 
FACS staining. Cells were trypsinized and resuspended in FACS buffer (PBS, 0.5% BSA, 
0.02% Sodium azide) at 4°C. Antibody staining was performed with 1:100 isotype-ab 
(553951, BD Pharmingen), TNFR1-ab (559915, BD), TNFR2-ab (559916, BD) followed by 
1:200 secondary biotinylated Goat anti-Hamster antibody (127-065-160, Jackson 
Immunoresearch), then with 1:200 SAV-APC (554067, BD). Staining was analyzed with 
FACS analyzer (Partec, Germany). Curves were smoothed for better visualization of the 
results. 
Western blot. Cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 
mM EDTA 1 mM PMSF, 1% NP40, 10% glycerol, protease inhibitors) and protein 
concentration was measured using BCA (Pierce). 20 µg of total proteins were run with Tris-
Tricine SDS-PAGE [149]. Western blotting was performed at 4°C and blot was blocked with 
5% milk powder (Biorad) in TBS-T overnight. Staining was performed with 1:5000 p65 
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antibody (sc-372 X, Santacruz), and 1:100'000 goat anti-mouse-HRP ab (Jackson 
Immunoresearch), and ECLplus (Amersham) reaction. Same blots were re-stained with 
1:2000 β-tubulin antibodies (Abcam). 
RNA isolation and gene expression analysis. Whole-cell RNA from cultured cells was 
extracted using TRIzol (Invitrogen) or peqGOLD RNAPure (peqLab) according to the 
manufacturer’s instructions. Subsequently, RNA was reverse-transcribed using random 
hexamers (Roche) and M-MuLV reverse transcriptase (Applied biosystems). The cDNA 
equivalent to 20 ng of total RNA was PCR-amplified in an ABI PRISM HT7900 detection 
system (PE-Applied Biosystems) using the TaqMan Universal PCR Master Mix (Applied 
Biosystems) and quantified as follows. Primers and probes for Taqman analysis were either 
purchased from Applied Biosystems or purchased from Microsynth, Balgach Switzerland as 
described in detail in SI table 1. The relative levels of each RNA were calculated by the 2-∆∆Ct 
method (Ct standing for the cycle number at which the signal reaches the threshold of 
detection); Gapdh mRNA was used as a housekeeping gene. Each Ct value used for these 
calculations is the mean of two duplicates of the same reaction. Relative RNA levels are 
expressed as x-fold variations compared to untreated. 
Chromatin immunoprecipitations. All steps were performed at 4 °C or on ice. About 1 x107 
cells per condition were used as starting material. Cells were fixed for 5 min at 37 °C with 1x 
PBS containing 1% formaldehyde. Subsequently, cells were washed twice with ice-cold 1x 
PBS and scraped in Glycin buffer (125 mM Glycine; 100 mM Tris, pH 9.4; 10 mM DTT). To 
stop fixation, cells were kept on ice for 15 min. After a short spin of 1,5 min, 2000 g, pelleted 
cells were resuspended in buffer I (0.25% Triton x-100; 10 mM EDTA; 1 mM EGTA; 10 mM 
HEPES, pH 6.5) by vortexing. Cells were pelleted at 2000 g, 5 min and carefully resuspended 
in buffer II (200 mM NaCl; 1 mM EDTA; 1 mM EGTA; 10 mM HEPES, pH 6.5). After 
another centrifugation for 5 min, 2000 g, nuclei were carefully resuspended in 190 µl nuclei 
resuspension buffer at RT (165 mM NaCl; 2.2 mM EDTA; 22 mM Tris-HCl, pH 8). After 
addition of 10 µl 20% SDS, nuclei were submitted to 5 x 1 min sonication steps with 30 sec 
pauses in between using the Bioruptor™ sonication machine (Diagenode, Liège, Belgium). 
The fragmented cross-linked chromatin was then diluted tenfold in dilution buffer (1.1% 
Triton X-100; 2 mM EDTA; 150 mM NaCl; 20 mM Tris-HCl, pH 8). 100 µl chromatin was 
used as starting material for DNA quantification experiments and 1 µl was used as input 
measurement. Immunoprecipitated DNA fragments captured by protein A–agarose/salmon 
sperm DNA (Millipore, Billerica, MA, USA) were washed sequentially with 500ml TSE I (20 
mM Tris-HCl, pH 8; 150 mM NaCl; 2 mM EDTA; 0.1% SDS; 1% TX-100), TSE II (20 mM 
 64
Tris-HCl, pH 8; 500 mM NaCl; 2 mM EDTA; 0.1% SDS; 1% TX-100), buffer III (0.25 M 
LiCl; 1% NP-40; 1% DOC; 1 mM EDTA; 10 mM Tris-HCl, pH 8) and TE buffer (10 mM 
Tris-HCl, pH 8; 1 mM EDTA) and the cross-links, including inputs, were reversed overnight 
at 65 °C in 20 mM Tris-HCl, pH 7.5; 150 mM NaCl; 2 mM EDTA; 1% SDS. DNA fragments 
were recovered using the DNA columns from the Qiagen MiniPrep kit according to the 
manufacturer’s protocol. Two microliters of each reaction were directly used in 10 µl real-
time PCR reactions using a 7900 HT machine (Applied Biosystems). The amount of DNA 
was quantified as described above. Each value was normalized to the corresponding input. 
Three independent experiments were done in duplicate or triplicate. The primers and Taqman 
probes used are listed in table 1. The antibody against acetylated histone H3 was purchased 
from Millipore.  
Nascient transcript assay. All steps were performed on ice or at 4 °C. 2 x107 cells were 
scraped and washed twice with PBS, resuspended in 400 µl of HB 0.3 M sucrose (10% 
glycerol, 0.3 M sucrose, 60 mM KCl, 15 mM NaCl, 15 mM HEPES, pH 7.9, 0.5 mM EDTA, 
0.15 mM spermine, 0.5 mM spermine, 0.5 mM PMSF, 1 mM DTT) and lysed by the addition 
of 400 µl HB 0.3 M sucrose containing 0.8% NP-40. After a 10 min incubation, nuclei were 
pelleted through a 1.2 ml cushion of HB 0.9 M sucrose by a 10 min centrifugation at 1500 g 
and resupended in 500 µl of nuclear suspension buffer (75 mM NaCl, 20 mM Tris-HCl, pH 
7.9, 0.5 mM EDTA, 0.125 mM PMSF, 0.85 mM DTT, 50% glycerol, 100 mg/ml tRNA). 
Nuclei were lysed on ice for 10 min in 2400ml nuclear lysis buffer (0.3 M NaCl, 20 mM 
HEPES, pH 7.6, 0.2 mM EDTA, 7.5 mM MgCl2, 1 M urea, 1 mM DTT, 1 % NP-40 and 100 
mg/ml tRNA). Chromatin was pelleted by 10 min at 15,000 g in a microfuge, resuspended in 
500 ml of chromatin suspension buffer (50 mM Na acetate, pH 5, 50 mM NaCl, 0.5% SDS, 
100 mg/ml tRNA), extracted three times with hot phenol mix (acid phenol saturated with 
water; 5 mM Na acetate, pH 5; 5 mM NaCl) at 65 °C. After addition of NaCl to a final 
concentration of 150 mM, nucleic acids were precipitated with ethanol, resuspended in 50 ml 
10 mM Tris-HCl, pH 7.5, and treated with RNase-free DNase to eliminate genomic DNA. 
Nascent transcripts were then extracted with phenol-chloroform, precipitated and resuspended 
in 30 µl of 10 mM Tris-HCl, pH 7.5. 10 µg were used for reverse transcription and real-time 
PCR, which were performed as described above. Results were corrected for cDNA input by 
amplifying nascent gapdh transcripts. The primers and Taqman probes used are listed in table 
1. 
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SUPPORTING INFORMATION 
 
 
 
Supplementary figure 1. The reduced levels of Dbp mRNA in NIH 3T3 fibroblasts is not due to an 
accelerated mRNA degradation. (A) Dbp mRNA degradation is very rapid. Cells were treated with 1 µg/ml 
Act D with or without 10 ng/ml TNF and collected after 30 or 75 min for mRNA quantification. Values are 
relative to untreated samples collected at time point 60 min. n = 1 in triplicates. (B) Cells were stimulated with 
10 ng/ml TNF overnight or left untreated. RNA was prepared for nascent transcripts analysis. n = 1 with one 
sample per condition. 
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Supplementary figure 2. Caspases are not involved in Per1 and Dbp regulations. NIH 3T3 cells were treated 
with 10 ng/ml TNF with or without 50µM Z-VAD-FMK simultaneously for 1 h. Values are relative to samples 
without TNF stimulation. Shown is one experiment done in triplicates. 
 
 
 
Supplementary Table 1. Sequences of primers and probes. 
 
 
 
Assay Gene FP Probe RP
nascent transcripts clock GGGATGGGTGGGTAATGTCA CAGAGAGTATTGGTACACAGGACAGCGTAGCA ACTACAGTTCTTAGGCGCACAGATG
dbp CTACGTTCCCGGATCCTACAC CCCATTCCCCAAGTGGATGGTGTT GATCCCGATATTCTCTTCTGCAA
per1 ACCAGCCATTCCGCCTAAC CTGCCTACTCATTGCCGAGCG CCTAGCCTATCCACCTTCATAACC
ChIP Dbp 857 ATGCTCACACGGTGCAGACA CCTAGTTTCCATGTGACCCTGCGAGG CTGCTCAGGCACATTCCTCAT
PCR tnfr1 ACCAAGTGCCACAAAGGAAC CACGCACTGGAAGTGTGTCT
tnfr2 TACCAAGGGTGGCATCTCTC TCCTGGGATTTCTCATCAGG
real time PCR dbp GCGAGAAGTGCAAAATTGGC CGCGCGCCTGTGTCCCTTG CGGGAGGCTCCTATAGTCTGG
clock TTGCTCCACGGGAATCCTT ACACAGCTCATCCTCTCTGCTGCCTTTC GGAGGGAAAGTGCTCTGTTGTAG
cry1 CTGGCGTGGAAGTCATCGT CGCATTTCACATACACTGTATGACCTGGACA CTGTCCGCCATTGAGTTCTATG
cry2 TGTCCCTTCCTGTGTGGAAGA CAGTCACCCTGTGGCAGAGCCTGG GCTCCCAGCTTGGCTTGA
SYBR green per1 1A TTACTCTGGAGCCGTCGAACTTGT AGGACGAAACAGGGAAGGTGAAGA
per1 1B GAACGGCCAGGTGTCGTGATTAAA AGGACGAAACAGGGAAGGTGAAGA
Pre-developed taqman assays (Applied biosystems)
real time PCR gapdh 4352339E
per1 Mm00501813_m1
per2 Mm00478113_m1
per3 Mm00478120_m1
dec1 Mm00478593_m1
dec2 Mm00470512_m1
IL-6 Mm00446190_m1
human gapdh 0-0702011
human dbp Hs00609747_m1
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ABSTRACT 
Tumour necrosis factor plays a key role in numerous sleep disorders. The hypothalamus is 
involved in the regulation of sleep and loss of hypothalamic neurons is a hallmark of 
narcolepsy. In order to identify TNF mediated neuronal dysfunctions we addressed the effect 
of TNF on hypothalamic neurons. The data show that TNF induces the expression of 
interferon type I and activates their downstream signalling pathways. Furthermore, TNF 
activates the transcription of chemokine and adhesion molecule genes. Thus, at least in-vitro, 
hypothalamic neurons respond to TNF by building up a protective state aimed at recruitment 
of leukocytes.  
 
INTRODUCTION 
Tumour necrosis factor (TNF) is a pleiotropic cytokine which is involved in many processes 
under both physiological and pathological conditions, ranging from cell growth and 
differentiation, to inflammation and mediation of immune responses, to regulation of 
apoptosis and necrosis. TNF is produced mainly by activated macrophages, lymphocytes and 
natural killer cells. In the CNS, TNF is also secreted by microglia and astrocytes [30]. There 
is increasing evidence suggesting that TNF plays a role in the pathology of sleep disorders 
such as narcolepsy, sleep apnoea, as well as fatigue associated with autoimmune diseases and 
infections. TNF concentration was found to be higher in narcoleptic patients compared to 
control subjects [150]. In patients with chronic insomnia, excessive daytime sleepiness, and 
obstructive sleep apnoea syndrome the circadian rhythm of TNF secretion was found to be 
different compared to healthy volunteers. The peak of secretion shifted from night-time to 
daytime [151]. 
The hypothalamus is considered a key centre for sleep regulation. Hypothalamic 
neurotransmitters are involved in many regulatory processes [152]. The hypocretin / orexin 
system is a critical regulator of sleep/wake state, feeding behaviour and reward processes. 
Hypocretin -1 and -2 are exclusively synthesized by neurons in the lateral hypothalamus. Loss 
of these neurons results in narcolepsy and cataplexy. 
In this report, we analysed the TNF-inducible gene-expression profile in murine hypothalamic 
neurons using DNA microarray technology. The data point to a strong focus of TNF to induce 
the expression of chemokine and chemokine receptor genes and of genes involved in cell 
migration and apoptosis.  
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METHODS 
Cell culture and stimulation. mHypoE-N1 cells were grown in DMEM (Gibco, Basel, 
Switzerland) supplemented with 10% FBS (PAA Laboratories, Pasching, Austria) and 
Glutamax (Gibco). For stimulation, cells were grown to confluency and the medium was 
replaced with serum-free DMEM/Glutamax with or without 10 ng/ml TNF.  
 
RNA extraction. After stimulation, cells were washed with cold PBS and lysed with 
peqGOLD RNA pure (PeqLab, Erlangen, Germany) according to the manufacturer’s 
instructions. Isolated RNA was thereafter DNA digested and purified with spin columns 
NucleoSpin RNA II (Macherey-Nagel, Düren, Germany).  
 
Gene expression arrays. Quality and quantity control of each RNA sample was performed 
on the 2100 Bioanalyzer. Gene expression array analysis was performed in the Functional 
Genomics Center Zurich using the Agilent Microarray system (Agilent Technologies). 
Cy3/Cy5-labeled cRNA were hybridized on Agilent GE Arrays (G4846A, Agilent 
Technologies) according to manufacturer’s protocol. The microarray analysis was performed 
in triplicates (3 diluent vs. 3 TNF treated). Slides were scanned using the Agilent DNA 
microarray scanner and the hybridization images were analysed with FeatureExtraction™ 
software. Genes were filtered according to their fold change and only genes exceeding a fold 
change of 2 up or down are reported.  
 
Flow cytometry staining. After stimulation, cells detached with 1 mM EDTA in PBS and 
resuspended in FACS buffer (PBS, 0.5% BSA, 0.02% sodium azide) at 4 °C. Antibody 
staining was performed with 1:100 isotype control antibodies (553954 BD Pharmingen and 
400406 Biolegend), VCAM1 antibodies (11-1061 eBioscience), FAS (554258, BD). 
Acquired data were analyzed using FlowJo software. 
 
Protein analysis. After stimulation, culture supernatants were collected and snap frozen in 
liquid nitrogen. Chemokine concentration was analyzed by Luminex technology at Cytolab, 
Dällikon, Switzerland.  
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RESULTS AND DISCUSSION 
Upon treatment of murine hypothalamic neurons (mHypoE-N1) with TNF, we found 456 
genes to be upregulated and 150 genes to be downregulated more than 2 fold. As shown in 
figure 1, the main groups of the upregulated genes comprise chemokines, their receptors, 
cytokines including interferons and their target genes, and genes involved in apoptosis. The 
genes induced more than 2 fold are listed in Table 1. 
 
 
 
Figure 1. . 22.8 % of the TNF induced genes are involved in cell-cell interaction, anti-viral protection and 
regulation of apoptosis. The genes represented in the chart are those induced more than 2 fold.  
 
 
Table 1. Genes upregulated more than 2-fold in TNF treated mHypoE-N1 
 
Gene name fold 
induction 
basal expression 
levels 
Group description 
CCL 5 / RANTES 66.8 M chemokines 
Ccl 20 / MIP-3 60.7 L chemokines 
ICAM1 / CD54 38.1 L membrane protein 
Cxcl 10 / IP-10 34.8 H chemokines 
Cxcl 11 / I-TAG 32.1 L chemokines 
Ifit3 IFN-induced protein (GARG-49) 16.1 H IFN related 
Ccrl 2 15.8 L membrane protein 
Irg1 Immune-responsive gene 1 13.2 L IFN related 
Ifit1 1 IFI-56K /GARG-16 12.7 H IFN related 
Cxcl 1 12.56 H chemokines 
Gbp2 IFN-induced guanylate-binding protein 2 12.5 H IFN related 
ICOS ligand / B7 11.8 M membrane protein 
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Gene name fold induction 
basal expression 
levels Group description 
FAS 10.7 H apoptosis 
TLR 2 10.4 H membrane protein 
Iigp1 IFN-inducible G5Pase 1 10.2 M IFN related 
MMP-13 9.9 M metalloprotease 
Ccl 7 / MCP-3 9.7 H chemokines 
Ifi47 IFNgamma-inducible protein 47 9.4 M IFN related 
Ccl 11 / Eotaxin 9.1 L chemokines 
Cxcl 16 9.1 M chemokines 
Gbp3 guanylate-binding protein 4 8.7 H IFN related 
Mx2 IFN-induced GTP-binding protein Mx2 7.6 H IFN related 
Naip2 Neuronal apoptosis inhibitory protein 2 7.6 M apoptosis 
VCAM-1 / CD106 precursor 7.5 H membrane protein 
Rtp4 Receptor-transporting  7.1 H IFN related 
Ccl 17 / TARC 6.6 M chemokines 
Ccl 9 / MIP-1 6.5 M chemokines 
Il-6 5.9 L cytokines 
Ltbp2 5.7 M cytokines 
Irgm2 IFN inducible GTPase 2 5.7 H IFN related 
CD83 5.6 L membrane protein 
Gbp1 5.5 M IFN related 
Irf5 IFN regulatory factor 5 5.5 M IFN related 
Cxcl 5 5.4 H chemokines 
MMP-3 5.4 M metalloprotease 
Birc3 Inhibitor of apoptosis protein 1 5.4 H apoptosis 
Oas2 2'-5' oligoadenylate synthase 2 5.2 M IFN related 
Flt1 / VEGF R1 5.2 M membrane protein 
Mycl1 L-myc-1 proto-oncogene protein 5.2 M apoptosis 
Tnfsf18 5.1 L cytokines 
GM-CSF 5.1 L cytokines 
Bid BH3-interacting domain death agonist 4.5 H apoptosis 
Cx3cl 1 / Fractalkine Receptor 4.4 H chemokines 
Bcl3 B-cell lymphoma 3-encoded protein homolog 4.4 H apoptosis 
Ccl8 4.2 M chemokines 
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                                  Gene name fold induction 
basal expression 
levels Group description 
Ifi44 IFNgamma-inducible protein 44 4.2 M IFN related 
ICAM -5 4.2 M membrane protein 
IL15ra / IL-15 receptor a 4.18 L membrane protein 
Cxcl 3 / MIP-2 4.1 L chemokines 
IL-15Ra Interleukin-15 receptor subunit alpha 4.1 L apoptosis 
Irf1 IFN regulatory factor 1 4 M IFN related 
Trim21 SS-A / 52kd Ro 3.9 M IFN related 
IL1rl 1 /IL-1 receptor-like 1 3.8 H membrane protein 
Ifi205 IFN-activatable protein 205-A 3.7 M IFN related 
Oas1a 2'-5' oligoadenylate synthase 1A 3.6 L IFN related 
Bmp3 / bone morphogenetic protein 3 3.5 L cytokines 
Irgm1 Immunity-related GTPase family M protein 3.5 H IFN related 
Ifi203 IFN-activatable protein 203 3.5 M IFN related 
Ccl 2 / MCP-1 3.4 H chemokines 
Csf1 / M-CSF 3.4 H cytokines 
Gvin1 very large inducible GTPase 1 3.4 M IFN related 
Il15 / IL-15 3.2 M cytokines 
Oas1f 2'-5' oligoadenylate synthase 1F 3.2 M IFN related 
Ifnar2 IFN-a/b receptor beta chain 3.2 H IFN related 
Gpr176 G protein coupled receptor AGR9 3.2 M membrane protein 
Ifih1 IFN-induced helicase C domain-containing 
protein 1 
3.1 M IFN related 
Ifi204 IFN-activatable protein 204 2.9 H IFN related 
Irf7 IFN regulatory factor 7 2.7 L IFN related 
Ifngr2 / IFNg receptor 2 2.7 H membrane protein 
Oasl 2'-5' oligoadenylate synthase 1 2.6 L IFN related 
Ifngr1 /IFNg receptor a chain 2.6 H membrane protein 
Irf9 IFN regulatory factor 9 2.5 L IFN related 
Ifnbeta1 IFN beta 2.5 L IFN related 
Myc Myc proto-oncogene protein 2.5 H apoptosis 
Cxcl 9 / MIG 2.4 L chemokines 
Ifi35 2.4 H IFN related 
IRF2 2.4 H IFN related 
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Gene name fold induction 
basal expression 
levels Group description 
Ifitm1 IFN induced transmembrane protein 1 2.4 M IFN related 
Il13ra1 / IL-13 receptor a-1 chain 2.4 M membrane protein 
Gpm6b neuronal membrane glycoprotein M6-b 2.4 L membrane protein 
CD274 / PD-L1 2.4 M membrane protein 
Osmr / Oncostatin-M specific receptor subunit b 2.4 H membrane pro 
Ier3 Radiation-inducible immediate-early gene IEX-1 2.4 H membrane protein 
Trp53 Cellular  tumour antigen p53  2.36 H apoptosis 
Gdnf / glia cell line-derived neurotrophic F 2.3 M cytokines 
Ifitm6 IFN induced transmembrane protein 6 2.2 M IFN related 
Ifitm3 IFN induced transmembrane protein 3 2.2 H IFN related 
Ifitm7 IFN induced transmembrane protein 7 2.2 H IFN related 
Eif2ak2 IFN-induced protein kinase 2.2 M IFN related 
Il13ra2 / IL-13 receptor a-2 chain 2.2 L membrane protein 
Wnt7b Protein Wnt-7b 2.18 L apoptosis 
Pim1 Proto-oncogene serine/threonine-protein kinase  2.17 M apoptosis 
ILrn / IL-1RA 2.1 L cytokines 
Ltb / Lymphotoxin-beta 2.1 L cytokines 
Wisp2 / connective tissue growth factor-like protein 2.1 M cytokines 
Il18rap Interleukin-18 receptor accessory protein 2.1 M membrane protein 
IL-6st / IL-6 receptor subunit b 2.1 H membrane protein 
Wisp2 / connective tissue growth factor-like protein 2.1 M membrane protein 
Il4ra / IL-4 receptor a-chain 2.1 M membrane protein 
Ifi202a IFN-activatable protein 202a 2 H IFN related 
Adora2b / Adenosin receptor A2b  2 M membrane protein 
 
 
TNF treatment results in upregulation of chemokines that act either on lymphocytes and 
macrophages (CCL5, CCL7, CCL9, CCL17, and CCL20) or on activated T-lymphocytes 
(CXCL10, CXCL11, CXCL16) and neutrophils (CXCL1, CXCL5). The expression of 
selected chemokines as detected by microarray technology was confirmed at the protein level 
by Luminex techniques. As shown in Figure 2 and Table 2, neurons respond to TNF with a 
time-dependent and pronounced secretion of CXCL10, CCL5, CXCL1 and CCL17. Among 
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the genes induced by TNF we found the adhesion molecules ICAM-1 and VCAM-1 to be 
strongly upregulated (38.4 and 7.5 fold respectively).  
 
 
 
 
Figure 2. To confirm the microarray data mHypoE-N1 culture supernatants were compared after 6 and 24 h of 
TNF treatment by Luminex assay. Data shown means ± SD. n=3. 
 
 
gene 
expression
protein concentration after TNF 
stimulation (ng/ml) 
Gene 
name 
n-fold 6 h 24 h 
Cxcl10 34.84 12.27 51.30 
Ccl5 66.86 1.78 8.63 
Cxcl1 12.56 5.43 11.79 
Ccl17 6.67 0.11 0.31 
 
Table 2. TNF -mediated upregulation of chemokine RNA expression and protein concentration in TNF 
stimulated mHypoE-N1 and their respective supernatants. 
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The two adhesion molecules, ICAM1 (Inter-Cellular Adhesion Molecule 1) and VCAM1 
(Vascular Cell Adhesion Molecule-1), which are essential in the T-cell adherence, e.g. on 
endothelial cells, were also among the genes strongly upregulated upon TNF treatment (38.4 
and 7.5 fold respectively).  
An increase of VCAM1expression on the cell membrane of TNF stimulated mHypoE-N1 
became visible by FACS analysis (Fig 3A). However, ICAM1 was not detectable on the cell 
surface (data not shown), although, as shown by microarray, the gene expression was strongly 
induced. Besides the effect of TNF on chemokines, their receptors, and genes involved in cell 
adhesion, 2.6 % of the genes induced by TNF are involved in apoptotic signalling, including 
the TNF receptor family member Fas. The expression of Fas became detectable by FACS 
analysis, the receptor being induced on the cell surface of TNF stimulated mHypoE-N1 (Fig. 
3B). 
 
 
 
Figure 3. The expression of VCAM1 and Fas was found to be induced by TNF. This result were further 
confirmed by FACS analysis after 24 h stimulation with TNF. A) VCAM1 staining, B) FAS staining. 
 
 
Taken collectively, the study presented here shows that hypothalamic neurons respond to TNF 
with upregulation of 450 genes. Among these 5.8 % are involved in communication with and 
between immune cells, such as lymphocytes, microglia / macrophages and astrocytes. It 
remains to be seen whether neurons of transgenic mice which express TNF in the CNS on 
astrocytes or oligodendrocytes also show altered expression of the genes which are found here 
to be modulated by TNF in mHypoE-N1 cells. 
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5. GENERAL DISCUSSION 
Sickness behaviour syndrome (SBS) has evolved in the process of natural selection 
throughout the animal kingdom as an adaptive response to systemic infection, helping the 
organism to cope with infection and improving chances of survival. However, SBS 
accompanies numerous pathological conditions including chronic inflammation in infectious 
diseases or autoinflammatory diseases and autoimmune diseases. In these conditions SBS is a 
maladaptive behaviour which has a huge impact on the quality of life of affected individuals. 
The cytokines discussed to mediate these behavioural changes are TNF, IL-1 and IL-6. These 
cytokines coordinate the local and systemic inflammatory response and also act on the brain 
to cause the behavioural symptoms of sickness [9]. Although the importance of these 
cytokines in mediating SBS has been assessed, their functional hierarchy in the cytokine 
network and the mechanisms underlying the various behavioural actions of these cytokines 
still remain elusive. 
In this thesis, a mouse model for sickness behaviour was established using CD40 ligation.  
Anti-CD40 antibodies bind to CD40 on innate immune cells mimicking the exaggerated 
CD40 activation induced by CD40L in autoimmune diseases. Excessive signalling through 
CD40-CD40L interaction is critically involved in the development of numerous animal 
models of autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and 
systemic lupus erythematosus [25]. Thus, our mouse model is likely to approach the situation 
of SBS in patients with autoimmune diseases. 
In this regard it is interesting that agonistic anti-CD40 has also therapeutic potential in the 
treatment of solid tumours and lymphomas, its applicability is however limited due to the 
occurrence of side effects such as fatigue, anorexia and headache [99]. 
Locomotor activity is one of the main circadian outputs and it is easily measured in rodents. 
Its decrease during pathological conditions belongs to the characteristics of sickness 
behaviour. Therefore, we monitored locomotor activity of individual mice in all our in vivo 
experiments. The nocturnal locomotor activity of mice treated with CD40 mAb significantly 
reduced the effect, returning to normal seven days after injection. The reduction in activity 
was paralleled by an increase in the number of sleep episodes longer than 5 minutes, 
indicating that as a sign for fatigue, the mice are most likely sleeping. During the light period, 
when mice usually rest, no increase in locomotor activity was observed, meaning that the 
distribution of activity remained within the normal circadian pattern.  
In order to understand the individual role of IL-6, TNF and IL-1 and their functional hierarchy 
within the cytokine network in inducing SBS, we addressed the effect of CD40 mAb 
 77
administration in IL-6-/-, TNFR1-/-, IL-1R1-/-, and MyD88-/- mice. Interestingly, all knockout 
strains analysed differed in their behavioural response to CD40 mAb treatment. Concerning 
nocturnal running wheel and infrared activity, IL6-/- mice responded similarly to wild type 
(see above), IL-1R1-/- showed a moderate response, whereas TNFR1-/- and MyD88-/- mice 
were completely protected from CD40 mAb mediated SBS.  
All three cytokines investigated here and especially IL-1 and TNF share numerous biological 
activities and induce the synthesis and release of each other. Moreover, IL-1 and TNF often 
exert additive or synergistic effects [42]. The complete unresponsiveness to development of 
CD40 mAb induced SBS as observed in TNFR1-/-, and the moderate response of IL-1R1-/- 
may point to the role of TNF to induce IL-1, which itself in a downstream step may amplify 
the action of TNF. This hypothesis was further validated by the observation that TNF 
injections mimic the effect of CD40 mAb and even restore the resistance seen in MyD88-/- 
mice. CD40 mAb challenged MyD88-/- mice had reduced levels of TNF in serum compared to 
wild type, suggesting that MyD88-mediated signalling events may be required for production 
of TNF in quantities necessary for SBS induction. This signal, though, is not transduced by 
IL-1 because IL-1R1-/- were still responsive to CD40 mAb. The intracellular adaptor protein 
MyD88 is used, not only by IL1R and IL18R, but also by all Toll like receptors (TLRs) 
(except TLR3) and interferon-regulated factors [102]. This suggests that a TLR ligand or IRF-
mediated signalling is required to induce TNF synthesis in MyD88 deficient mice. Though, 
the nature and the source of this signal remain elusive.  
Another important feature of SBS is weight loss which can arise from anorexia or cachexia, a 
highly complex metabolic disorder involving features of anorexia, anaemia, lipolysis and 
insulin resistance [153]. As true for locomotor activity, we observed difference in the degree 
of weight loss among the genotypes analysed. Compared to wild type, also IL-6-/- showed 
significant weight loss, excluding IL-6 as a possible mediator. This is surprising given the 
vast literature on the crucial role of IL-6 in the acute phase response and liver pathologies 
[154]. While weight loss in IL-1R1-/- was moderate, it was minimal in TNFR1-/-. Both TNF 
and IL-1 have been well established to mediate progressive weight loss. TNF is considered to 
be the most relevant cytokine in the development of cachexia seen in chronic illnesses. 
Intraperitoneal injection of IL-1 induces a reduction in total caloric intake in rats, suggesting 
that IL-1 may also contribute to anorexia. IL-1 might activate CNS structures involved in food 
intake and energy homeostasis via its action on the vagus nerve [155]. Since MyD88-/- mice 
were completely protected from CD40 mAb-induced weight loss, MyD88 though is not 
involved in CD40 signalling. In summary, since MyD88-/- mice have reduced levels of TNF in 
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serum compared to wild type, and IL-1R1-/- are partially resistant, we conclude that IL-1 and 
TNF have additive effects in SBS. The drastic effect observed in TNFR1-/- may indicate that 
TNF is a stronger inducer of weight loss and that IL-1 potentiates its effect. 
The physiological and behavioural changes that are characteristic for sickness are controlled 
by the central nervous system. Cytokines, including TNF and IL-1, can be synthesized and 
released directly within the CNS, where they are produced mainly by microglia, astrocytes 
and neurons [156]. It has been difficult to identify TNFR and IL-1R1 expression in the brain 
of healthy rodents, probably reflecting low density of receptor expression and poor sensitivity 
of the techniques used. Nevertheless, TNFR1 expression has been reported in multiple brain 
regions, including the choroid plexus, the cerebellum, the cortex and the hippocampus [157]. 
In contrast, TNFR2 expression was not detectable within the brain [158]. IL-1R1 expression 
was detected in the hippocampus, amygdala and mediodorsal thalamic nucleus. In the 
paraventricular hypothalamic nucleus the signal of IL-1R1 mRNA was found only on blood 
vessels [159-160]. Therefore, the next challenge in clarifying the mechanism of cytokine 
induced SBS is to identify which cell type needs to express cytokine receptors and whether 
these are required in the periphery or in the CNS. 
In order to assess whether the expression of the receptor on immune cells invading the CNS is 
sufficient to induce SBS or whether the receptor has to be expressed within the CNS, we will 
generate bone marrow chimeras using bone marrow of TNFRI-/- or wt for engraftment into wt 
and TNFRI-/- mice respectively and analyse the effect of anti-CD40 treatment in these mice. 
As mentioned above, in the CNS cytokines are synthesized mainly by microglia and 
astrocytes. However, SBS is the result of altered neuronal outputs. Therefore, it would be 
particularly interesting to investigate the role of TNFR1 expressed in neurons. By crossing 
mice expressing the Cre recombinase under the promoter of the neural stem cell specific gene 
Nestin with floxed TNFR1 mice, it is possible to knockout the TNFR1 only in CNS derived 
cells. Moreover, investigating the distribution of cytokine expression in the different brain 
regions upon CD40 mAb in wild type and the different knockout mice used by 
immunohistochemistry, particularly in the SCN, would further contribute to understanding 
where cytokine expression is essential in order to induce sickness behaviour.  
The impact of circadian timing on our health has gained increasing attention in the last 
decade, and circadian dysfunction is thought to contribute to the incidence of a wide range of 
diseases, including sleep disorders, cancer, depression and inflammation. Though, a link 
between core clock proteins with inflammatory pathways has only recently begun to emerge. 
Evidence from both in vitro and in vivo studies suggests the pro-inflammatory cytokine TNF 
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can modulate the expression of clock genes Period, Rev-Erbα and of the clock-controlled 
genes Dbp, Hlf and Tef, both in fibroblasts in vitro and in the liver [92]. Here we showed 
CD40 mAb treatment also leads to suppression of Period and Rev-Erbα genes and of Dbp, Hlf 
and Tef. As expected, the reduced expression of Rev-Erbα was parallel by upregulation of 
Bmal1. Rev-Erbα inhibits Bmal1 transcription by binding to RORE DNA sequences in its 
promoter [65]. Noteworthy, as true for CD40 mAb-mediated impairment of locomotor 
activity with increased rest periods, also the CD40 ligation-induced dysregulation of clock 
gene expression depends on TNFR1 and partially on IL-1R1, but not on IL-6. As shown by 
luciferase reporter assays, TNF impairs transcription of E-box containing constructs [92]. This 
finding was further validated here by BMAL1 chromatin immunoprecipitation, showing 
impaired BMAL1 binding to E-boxes in the respective Dbp and Rev-Erbα promoters at ZT9 
in CD40 mAb treated animals compared to control. This effect was seen only in nuclear liver 
extracts obtained from CD40 mAb treated wt, but not when derived from TNFR1-/- mice 
exposed to CD40 mAb.  
A series of studies indicate that activation of CCGs by CLOCK:BMAL1 is coupled to 
circadian changes in histone modifications at their promoter [103]. Indeed, we found that 
circadian transcription of Dbp and Rev-Erbα is accompanied by acetylation of Histones H3 at 
lysine 9. CD40 treatment lowered only the levels of AcH3K9 at the E-boxes of Dbp and Rev-
Erbα in liver samples from wt mice, but not from TNFR1-/- mice. Thus transcriptional clock 
gene deactivation by CD40 as judged by acetylated H3 is dependent on TNF signalling. The 
transcription factor CLOCK has intrinsic histone acetyl transferase (HAT) activity. Using 
mouse embryonic fibroblasts derived from homozygous Clock mutant, it was shown that the 
HAT function of CLOCK is essential for the circadian control of CCGs [161]. Acetylation of 
proteins has been reported to be an essential regulatory mechanism, stimulating or inhibiting 
transcription. The dimerization partner of CLOCK, BMAL1 is acetylated by CLOCK with a 
diurnal rhythm in the liver. The timing of BMAL1 acetylation parallels the down regulation of 
circadian transcription of clock-controlled genes. Recently, the histone deacetylase sirtuin 1 
(SIRT1) was identified as a crucial modulator of the circadian clock machinery by 
counteracting the HAT activity of CLOCK [162]. SIRT1 plays a crucial role in metabolism 
and survival by deacetylating several proteins and regulating gene expression through histone 
deacetylation. An interesting hallmark of SIRT1 is that its enzymatic activity is NAD+-
dependent. As the NAD+/NADH ratio is a direct measure of the energy status of a cell, the 
NAD+ dependence of SIRT1 directly links cellular energy metabolism to gene transcritpion 
[163]. The reduced form of both redox cofactor, NAD(H) and NADP(H) have been shown to 
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strongly enhance DNA-binding of the CLOCK:BMAL1 complex, whereas the oxidized form 
inhibits binding [164].  
In this scenario it can be envisaged that an immune response may also have effects on the 
circadian clock. NADPH oxidase enzymes are present in most tissues and catalyze the 
reduction of molecular oxygen to superoxide anions by the transfer of electrons from 
NAD(P)H. These reactive oxygen species (ROS) contribute to clearance of pathogens in 
innate immunity and function as signalling molecules in various cellular processes, including 
apoptosis and necrotic cell death. TNF is a potent inducer of ROS production. Recently, the 
mechanism, through which TNF activates the NADPH oxidases NOX1 and NOX2, has been 
revealed. The riboflavin kinase (RFK) was identified as a TNFR1-binding protein that couples 
TNFR1 to NADPH oxidase. RFK binds to both the TNFR1-death domain and to p22phox, the 
common subunit of NADPH oxidase isoforms NOX1 and NOX2 [165]. TNF, through 
activation of RFK, enhances the incorporation of the rate-limiting cofactor FAD in NADPH 
oxidase (Figure 5). In an in vitro experiment, we will investigate whether TNF-induced 
reduction of E-box-bearing clock genes can be reversed by inhibiting the production of ROS 
with antioxidants, such as N-acetyl-cystein. 
In conclusion, it seems reasonable that cytokines by altering the metabolic state of cells lead 
to clock gene dysregulation. This in turn may lead to lowering the metabolic rate in order 
conserve energy by turning off appetite to avoid the urge to search for food, and by causing 
fatigue encouraging the animals to remain in a save place minimizing energy expenditure. 
We have shown that TNF:TNFR1 interactions in CD40 mAb treated mice lead to increased 
rest periods and altered clock gene responses. The important question is whether these parallel 
outcomes are indeed linked to each other. We found significant correlations between the 
magnitude of CD40 mAb-triggered impairment of locomotor activity and dysregulation of 
clock genes in the different knockout mice studied. Mice with the most dramatic CD40 mAb-
reduction in locomotor activity also showed the most pronounced decrease of Dbp expression. 
Expression of Rev-Erbα showed a trend in the same direction, whereas Bmal1 expression 
tended in the opposite direction when correlated to reduction in locomotor activity, though 
both did not reach significance. Noteworthy is the intermediate expression of clock genes 
shown by IL1R1-/- and TNFR1+/-, which is reflected in their moderate loss of activity.  
We could observe an association between sickness behaviour and deregulated clock gene 
expression, but at this point we do not know if the impairment of the circadian clock is the 
cause or barely the consequence of altered physiology which accompanies the sickness 
behaviour syndrome. This is a challenging issue to address. Mice lacking the core clock 
 81
component Bmal1 have completely disturbed circadian rhythms and are in this regard suitable 
to assess whether disturbance of the circadian clock per se has an impact on the function of 
the immune system. Bmal1-/- mice, however, because of the involvement of the core clock 
proteins in multiple physiological and metabolic processes, have severely compromised 
physiology and already at the age of 16 weeks show signs of aging, such as weight loss, loss 
of muscle tone accompanied by reduced locomotor activity and osteoporosis [86]. Being 
aware of these difficulties, we will assess cytokines in the serum of naïve and CD40 mAb 
challenged Bmal1 knockout mice younger that ten weeks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. A schematic model illustrating a hypothetical link between TNF signalling and the 
circadian clock (Inspired by [164] and [165]). 
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The classical view of cytokine mediated sickness behaviour suggests that a peripheral 
infection ultimately leads to cytokines release in the brain, where they act on the different 
neuronal centres thereby affecting behaviour. Here, an additional mechanism emerges. 
Cytokines may act on peripheral organs and dampen the amplitude of their circadian clocks, 
and thus modifying their metabolic activity. These may in turn cause alterations in the clock 
outputs modifying behaviour and physiology, leading to the appearance of sickness behaviour 
syndrome. 
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